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 In the United States, approximately 13% of the annual birth cohort is born preterm 
(<37 weeks gestational age). These infants are at high risk of systemic infections, and most 
are treated with antimicrobial agents. In spite of their common use, antimicrobials lack 
pharmacokinetic (PK) data in preterm infants. Extrapolation of dosing information from 
older children and adults to preterm infants often results in therapeutic failures or unwanted 
toxicities. Therefore, PK studies in this population are needed. Unique challenges posed by 
preterm infants, however, limit the ability to evaluate drug disposition in this population. 
Novel, minimal-risk methods can provide the platform to overcome these challenges and 
optimize antimicrobial dosing. In this proposal, several of these methods were employed to 
deliver antimicrobial dosing recommendations specifically designed for preterm infants. Two 
commonly used antimicrobials, piperacillin and metronidazole, were used to evaluate the 
utility of these methods. A multiplex liquid chromatography-tandem mass spectrometry 
assay for the simultaneous quantification of ampicillin, piperacillin, tazobactam, meropenem, 
acyclovir, and metronidazole in ultra-low (<50 uL) human plasma was developed and 
validated. This method was used to analyze drug concentration data from sparse, scavenged, 
and dried blood spot PK samples collected from preterm infants <32 weeks gestational age at 
birth. The scavenged concentration data were analyzed by population PK methodologies and
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used to derive PK parameters and identify covariates (serum creatinine and postmenstrual 
age) that explain inter-individual variability in piperacillin and metronidazole clearance. 
When compared to historical data from small studies using traditional PK sampling, 
piperacillin concentrations were 2–10-fold lower in the scavenged sampling approach, which 
prevented the determination of optimal dosing recommendations for piperacillin. In contrast, 
scavenged sampling proved successful for metronidazole and allowed for the development of 
a simplified, postmenstrual age-based dosing regimen. Piperacillin and tazobactam dried 
blood spot sampling proved successful as a proof-of-concept application. Dried blood spot 
piperacillin and tazobactam concentrations can be used as surrogate for plasma 
measurements. Novel, minimal-risk methods are powerful tools to evaluate the 
pharmacokinetics/pharmacodynamics of antimicrobials in preterm infants. The success of 
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 Infections in preterm infants are common and fatal.1,2 Approximately 20% of very-
low-birth-weight (<1500 g) infants suffer from culture-proven sepsis, and 10–20% die from 
sepsis in spite of antimicrobial therapy.1,2 Among extremely-low-birth-weight (<1000 g) 
infants, infection is associated with poor neurodevelopmental outcomes.3 To prevent these 
devastating consequences, more than 90% of infants born <33 weeks gestational age who are 
admitted to the nursery are treated with multiple antimicrobial agents.4 
 In spite of their common use, over 50% of antimicrobials are prescribed off-label in 
the nursery,5–7 and most lack some aspect of pharmacokinetic (PK) information specific to 
infants. Off-label prescribing based on extrapolation of dosing recommendations from older 
children or adults results in adverse drug effects or lack of efficacy.8–10 The latter is likely 
due to the unique and complicated physiology of preterm infants, which differs greatly from 
older children and adults. These differences include a larger extracellular fluid volume, 
immature renal and hepatic function, underdevelopment of metabolic enzymatic systems, and 
a unique blood-brain barrier—all of which can alter drug disposition significantly.11 As a 
result, antibiotic dosing used in adults (normalized by body weight) and extrapolated to 
premature infants may result in efficacy failures or unwanted toxicity. The combination of 
these factors underscores the critical need for PK and safety studies specifically designed for 
the preterm infant population.
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 Several limitations inherent to trials involving preterm infants, however, prevent 
researchers from pursuing the study of drugs in this population. These include low rates of 
informed consent among parents of critically ill infants; limited blood volume necessary to 
conduct PK studies; lack of availability of sensitive multiplexed analytical methods to 
measure drug concentrations; lack of population PK analysis expertise in the pediatric field 
capable of analyzing sparse PK data; and difficulties associated with pre-specified timing of 
blood samples for PK analysis.  
 To overcome these challenges, novel minimal-risk methods to evaluate the PK of 
antimicrobials in infants are needed. These methods include sparse and scavenged sampling, 
multiplex drug assays in ultra-low plasma volumes, population PK analyses using pediatric 
data, and alternative biological matrices such as dried blood spots (DBS). Even though the 
implementation of these methods could result in specific dosing recommendations for 
preterm infants, most have not been systematically studied in this population.  
 A minimal-risk method to obtain sparse samples is the collection of scavenged 
samples left over from the normal clinical care of infants. Once collected, these samples are 
sent to clinical laboratories for chemical and hematological assays. Blood sent to laboratories 
is often in excess of what is needed for the laboratory assay, and this surplus can be saved for 
PK analysis. The use of scavenged samples for PK studies in preterm infants offers several 
advantages over traditional timed PK trials. These include avoiding the need for heel sticks 
specifically for the study; higher rates of parental consent; availability of several samples per 
infant; and avoidance of time-specific sampling. Possible disadvantages include drug 
stability problems associated with inappropriate sample storage; unsuitable draw times not 
useful for PK analysis; and low volume of surplus blood. Most of these limitations can be 
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overcome by the availability of several samples per patient, use of new methodologies for 
estimating PK parameters such as population PK analyses, and sensitive multi-drug 
concentration assays that can detect several drugs in the same sample. 
 The use of sparse sampling and population PK approaches have been most 
extensively studied with drugs such as vancomycin and gentamicin because these agents are 
subjected to routine therapeutic drug monitoring in the clinical setting. Other drugs for which 
this type of analysis has proven successful in preterm infants include fluconazole,12 
cefepime,13 and amoxicillin.14 In these studies, the use of sparse sampling resulted in changes 
of dosing recommendations for preterm infants.  
 Another methodology that could advance PK studies in preterm infants is multiplexed 
bioanalytical chemistry methods that can simultaneously measure multiple drugs in ultra-low 
(<100 µL) plasma volumes.15 Using the simultaneous measuring approach, this technology 
maximizes the drug concentration information obtained from each PK sample. This 
methodology has been successful in several settings including measurement of 17 
antiretroviral drugs from different drug classes in 50µL of human plasma16 and simultaneous 
measurements of 5 beta-lactam antibiotics (cefepime, ceftazidime, cefuroxime, meropenem, 
and piperacillin) and 7 antimicrobials (cefuroxime, cephalexin, ceftazidime, ampicillin, 
benzylpenicillin, metronidazole, and chloramphenicol) of different classes.17,18 In infants, the 
multiplex-assay approach is attractive because they are often treated with several 
antimicrobials concomitantly. More importantly, in the setting of clinical trials where each 
infant receives a different antimicrobial agent, a single multiplex assay increases trial 
efficiency by measuring drug concentrations of all agents without the need to develop and 
validate multiple individual assays specific for each drug.  
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  Even though novel, ultra-sensitive bioanalytical assays have substantially decreased 
the amount of plasma required to measure drug concentrations in preterm infants, traditional 
PK plasma sampling still involves the collection of ~200 µL of whole blood for each PK 
sample. This requirement is due to the need for separation of plasma or serum from the 
cellular components of whole blood. As such, the blood volume required per sample is 
usually double the amount of plasma needed for analysis, thereby increasing the amount of 
sample collected unnecessarily. In addition, sample processing times and personnel training 
are required to maintain a controlled sample collection environment. Over the past few years, 
a novel sample collection method using DBS has emerged and is increasingly employed by 
the pharmaceutical industry in drug development.19 This method involves the collection of 
15–30 uL of whole blood on blotting paper. Potential advantages of this approach include 
low sample volume, minimal personnel training, no sample processing (sample is collected 
as a final product at the patient bedside), room temperature storage, and simple sample 
extraction. These properties make DBS sampling an attractive technology for PK sampling in 
infants.  
 DBS sampling has been used in the newborn metabolic diseases screening program 
over the past 5 decades; however, its application in clinical PK trials is limited. Several 
investigators have successfully demonstrated the ability of DBS to reflect traditional whole 
blood and plasma drug concentrations in adult clinical trials.20–22  
 The studies conducted under this dissertation proposal involve the use of minimal-
risk methods to evaluate the PK/pharmacodynamics (PD) of antimicrobials in preterm 
infants. Two antimicrobials, piperacillin and metronidazole, were chosen to evaluate the 
utility of these minimal-risk methods. These antimicrobials were selected because they are 
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commonly used in preterm infants, there is minimal PK/PD information in the published 
literature, they exhibit different elimination pathways, and they possess different 
physicochemical properties, all of which can alter the success of the minimal-risk methods 
evaluated. The combination of these factors will allow the thorough evaluation of these 
methods to determine the most useful tools to evaluate the PK/PD of antimicrobials in 
preterm infants and revolutionize the way PK studies are conducted in this vulnerable 
population.  
 The hypothesis of this proposal is that scavenged blood samples can be used in 
infants to generate antimicrobial PK/PD relationships and provide evidence-based dosing 
recommendations. Additionally, dried blood spot technology can provide similar data to 
plasma sampling with less invasive collection techniques. 
 AIM 1: Develop and validate a multiplex drug concentration assay containing 
ampicillin, piperacillin/tazobactam, acyclovir, metronidazole, and meropenem in 50 uL of 
infant plasma using mass spectrometry with a lower limit of quantification appropriate for 
scavenged sampling. A high-performance liquid chromatography-tandem mass spectrometry 
method will be developed and validated according to Food and Drug Administration criteria 
to measure drug concentrations of 5 commonly used antimicrobials in 50 uL of infant plasma 
with intra- and interday accuracy and precision of 85–125% and >80%, respectively. 
 AIM 2: Determine the pharmacokinetics and pharmacodynamics of piperacillin and 
metronidazole in premature infants using scavenged samples.  
AIM 2a: Develop a pharmacokinetic model of piperacillin and metronidazole 
in premature infants. Developing this model will show that the clearance of 
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piperacillin and metronidazole are directly related to postmenstrual age, 
requiring new dosing recommendations adjusted by this factor. 
AIM 2b: Determine the likelihood of achieving an optimal pharmacodynamic 
target for piperacillin and metronidazole with current dosing 
recommendations. This analysis will demonstrate that current dosing 
recommendations for piperacillin and metronidazole will achieve the optimal 
pharmacodynamic target in less than 50% of infants. The target for 
piperacillin use in bacteremia is a time above the minimum inhibitory 
concentration-90 of at least 75% of the dosing interval; the target for 
metronidazole use in intra-abdominal infections is trough concentrations 
higher than 8 mg/L. 
 AIM 3: Determine the comparability of piperacillin drug concentrations in plasma 
and dried blood spots samples. For piperacillin, an optimal blood spot extraction method will 
be developed and stability will be quantified. The comparability between piperacillin drug 
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CHAPTER I: DEVELOPMENT OF A LIQUID CHROMATOGRAPHY-TANDEM MASS 
SPECTROMETRY ASSAY OF SIX ANTIMICROBIALS IN PLASMA FOR 
PHARMACOKINETIC STUDIES IN PREMATURE INFANTS 
 
Introduction 
 Infections in premature infants (<37 weeks gestation at birth) are common and 
fatal1,2; approximately 20% of very-low-birth-weight (<1500 g) infants suffer from culture-
proven sepsis, and 10–20% die.1,2 To prevent these devastating consequences, more than 90% 
of infants born <33 weeks gestational age and admitted to the nursery are treated with 
multiple antimicrobial agents.3 In spite of the widespread use of antimicrobials in this 
population, pharmacokinetic (PK) studies in premature infants are exceptionally scarce. This 
is due, in part, to limitations inherent to trials involving premature infants, including limited 
blood volume necessary to conduct PK studies and lack of availability of sensitive and 
specific drug concentration assays.  
 Over the last 2 decades, advances in technology have provided tools to measure drug 
concentration in biological matrices accurately, selectively, and with increased sensitivity. 
Optimized methods using high-performance liquid chromatography (HPLC) and the 
incorporation of mass spectrometry (MS) have resulted in the ability to measure drug 
concentrations in low (<100 uL) plasma volume. In addition, given the ability of these 
instruments to separate compounds efficiently, it is now possible to measure several 
compounds in the same sample simultaneously.4 This methodology has been successful in 
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several settings, including measurement of antiretroviral drugs from different drug classes5 
and simultaneous measurements of antimicrobials.6,7 In premature infants, the multiplex-
assay approach is attractive because these patients are often treated with several 
antimicrobials concomitantly. More importantly, in the setting of clinical trials where each 
infant receives a different antimicrobial agent, a single multiplex assay increases trial 
efficiency by measuring drug concentrations of all agents without the need to develop and 
validate multiple individual assays specific for each drug. Therefore, the purpose of this work 
was to develop and validate a LC–MS/MS multiplex drug concentration assay for commonly 
used antimicrobials in premature infants, including ampicillin, piperacillin, tazobactam, 
meropenem, acyclovir, and metronidazole. 
 
Methods 
Chemicals and reagents 
 Ampicillin, piperacillin, acyclovir, metronidazole, and dicloxacillin (internal standard 
[IS]) were purchased from the Sigma Chemical Company (St. Louis, MO, USA). 
Tazobactam and meropenem were purchased from the U.S. Pharmacopeia (Rockville, MD, 
USA). HPLC-grade chemicals were purchased from Fisher Scientific (Norcross, GA, USA). 
Purified compressed nitrogen was obtained from Airgas-National Welders (Charlotte, NC, 
USA). Drug-free pooled plasma was obtained from Biological Specialty Corporation 
(Colmar, PA, USA). Plasma obtained from whole blood anticoagulated with potassium 






 Compounds were analyzed with a triple quadrupole mass spectrometer API 4000 
(Applied Biosystems–ABSciex, Foster City, CA, USA). A Shimadzu solvent delivery system 
(Columbia, MD, USA), LEAP HTC PAL thermostatted autosampler (Carrboro, NC, USA), 
Valco switching valve (Houston, TX, USA), and Analyst Software version 1.4.1 (Applied 
Biosystems–ABSciex, Foster City, CA, USA) run on a Dell desktop computer (operated by 
Windows XP professional) were used for this method. 
 
Preparation of standards 
 Individual clear stock solutions of ampicillin, piperacillin, tazobactam, meropenem, 
acyclovir, and metronidazole were prepared at the following concentrations: ampicillin, 
piperacillin, and tazobactam 15 mg/mL, meropenem and acyclovir 5 mg/mL, and 
metronidazole 2.5 mg/mL. Each analyte was accurately weighed and dissolved in dimethyl 
sulfoxide (DMSO) according to Table 1.1. 
 The master stock solution was prepared as a composite of all 6 compounds (0.5 mL 
each), adjusted to a final concentration of 1,500,000 ng/mL for ampicillin, piperacillin, and 
tazobactam; 500,000 ng/mL for meropenem and acyclovir; and 250,000 ng/mL for 
metronidazole, by 2.0 mL of DMSO. This master stock standard was used to prepare 7 
intermediate composite stock solutions: ampicillin and piperacillin (1,500,000; 750,000; 
300,000; 150,000; 30,000; 15,000; and 3,000 ng/mL); tazobactam (750,000; 300,000; 
150,000; 30,000; 15,000; 3,000; and 1,500 ng/mL); meropenem and acyclovir (500,000; 
250,000; 100,000; 50,000; 10,000; 5,000; and 1,000 ng/mL); and metronidazole (250,000; 
125,000; 50,000; 25,000; 5,000; 2,500; and 500 ng/mL) in DMSO.  
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 Plasma working calibration solutions at 150,000, 75,000, 30,000, 15,000, 3,000, 
1,500, and 300 ng/mL for ampicillin and piperacillin; 75,000, 30,000, 15,000, 3,000, 1,500, 
300, and 150 ng/mL for tazobactam; 50,000, 25,000, 10,000, 5,000, 1,000, 500, and 100 
ng/mL for meropenem and acyclovir; and 25,000, 12,500, 5,000, 2,500, 500, 250, and 50 
ng/mL for metronidazole were prepared by diluting the intermediate solutions in human 
drug-free plasma in a ratio of 1:9.  
 From the master and intermediate stock solutions, quality control (QC) intermediate 
stock solutions were prepared in DMSO at concentrations of 9,000, 600,000, and 1,200,000 
ng/mL for ampicillin and piperacillin; 4,500, 180,000, and 600,000 ng/mL for tazobactam; 
3,000, 200,000, and 400,000 ng/mL for meropenem and acyclovir; and 1,500, 100,000, and 
200,000 ng/mL for metronidazole. Plasma working QC samples of 900, 60,000, and 120,000 
ng/mL for ampicillin and piperacillin; 450, 18,000, and 60,000 ng/mL for tazobactam; 300, 
20,000, and 40,000 ng/mL for meropenem and acyclovir; and 150, 10,000, and 20,000 ng/mL 
for metronidazole were prepared by diluting the QC intermediate solutions in human drug-
free plasma in a ratio of 1:9.  
 
Internal standard preparation 
 Dicloxacillin (1 mg) was weighed and dissolved in DMSO to achieve a final 
concentration of 1.0 mg/mL (stock solution). The internal standard working solution was 
prepared by diluting 0.3 mL of this solution in 99.7 mL of acetonitrile to achieve a final 





Samples and pre-treatment 
 This method was used to measure antimicrobial concentrations in clinical samples 
collected from premature infants at pre-specified time points or scavenged from the clinical 
laboratory after processing for clinical care. Sample collection (~200–1000 µL, heparinized 
or EDTA tubes) occurred under an investigational protocol approved by the institutional 
review board at participating sites and after informed consent was obtained from caregivers 
of study participants. Blood samples at pre-specified time points were collected and kept on 
ice after collection for a maximum of 15 minutes. Blood plasma was separated by 
centrifugation for 10 minutes. Plasma samples were transferred to a −80° C temperature-
monitored freezer for storage until analysis. Prior to extraction, all plasma samples were 
brought to room temperature and then gently mixed. 
 
The extraction procedure 
 On the day of analysis, 200 μL of chilled (left in the refrigerator for 20 minutes) 
internal standard was placed into a 2.0 mL labeled conical plastic Eppendorf tube, followed 
by 45 μL of plasma and 5 μL of DMSO (for blank and patient samples) or by 50 μL of spiked 
plasma (for calibrators and QC samples). The DMSO was added to the blank and patient 
samples to compensate for the DMSO added to the plasma working calibration solutions. The 
solutions were vortex-mixed for 15 minutes and centrifuged at 15,600 g at 4o C for 10 
minutes. The supernatant portion was transferred into a 96-insert holder with 0.7 mL glass 






 Ampicillin, piperacillin, acyclovir, meropenem, and metronidazole were analyzed in 
positive mode. Tazobactam was analyzed in negative mode during a separate injection run 
from the same glass insert. Dicloxicillin was used as internal standard for both positive and 
negative analyses. The injection volume was 4 µL. 
 Chromatography was achieved by using a reverse-phase C18 Aquasil column (50 x 
2.1-mm internal diameter, 5 μm particle size; Thermo Fisher, Waltham, MA, USA) with a 
flow rate of 0.75 ml/min for analysis in positive mode and a C18 Ultra Aqueous column (50 
x 2.1-mm internal diameter, 3 μm particle size; Restek, Bellefonte, PA, USA) with a flow 
rate of 0.35 ml/min for analysis in negative mode. In both analyses, mobile phase A consisted 
of 0.1% formic acid in water, and mobile phase B consisted of 0.1% formic acid in methanol. 
The chromatographic separation of analytes was performed with gradient elution of 
increasing mobile phase B (0% hold until 0.7 minutes, 0–15% from 0.7–1 minute, 15–100% 
from 1–4 minutes, 100% hold from 4–4.5 minutes, 0% from 4.5–6 minutes for positive 
mode; 0% hold until 0.7 minutes, 0–100% from 0.7–2.5 minutes, 100% hold from 2.5–3.5 
minutes, 0% from 3.5–5 minutes for negative mode). Flow was diverted to waste for the first 
0.7 minutes and after 4 minutes. Total run time was 6 and 5 minutes for positive and negative 
mode, respectively. 
 MS/MS analysis was performed on a triple quadrupole mass spectrometer API 4000 
(Applied Biosystems–ABSciex, Foster City, CA, USA) operated with electrospray ionization 
(TurboV source using the electrospray probe). Ionspray voltage and turbo heater temperature 
were kept at 2500 V (-2000 V for tazobactam) and 500o C, respectively. Compound-specific 
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instrument parameters were optimized for each transition (Table 1.2) to obtain the most 
robust signal. 
 
Linearity, limit of quantification, and limit of detection 
 Linearity was assessed using 5 calibration curves analyzed on separate days. For 
validation, each point on the calibration curve was run in duplicate (2 separate extractions), 
and the curves were constructed by calculating the peak area ratios of each compound to the 
internal standard and plotting these against the nominal concentration of the sample. Back-
calculated calibration concentrations were determined using several models. The calibration 
curve with the best accuracy and precision throughout the curve range was considered the 
best fit. Quadratic regression of the ratio of compound to internal standard concentration (x) 
versus peak area ratio of compound to internal standard (y) using a 1/(x) weighting scheme 
was used for calculations because it provided the best fit to the data.  
 The upper limit of quantification (ULOQ) was defined as the highest standard 
concentration for which both the relative standard deviation and the percent deviation from 
the nominal concentration were less than 15%.8 The lower limit of quantification (LLOQ) 
was defined as the lowest concentration for which both the relative standard deviation and 
the percent deviation from the nominal concentration were less than 20%. The detection limit 
was defined as signal to noise ratio of 3:1. 
 
Matrix effects 
 Seven different lots from 2 separate plasma matrices (2 lots sodium heparin and 5 lots 
potassium triphosphate EDTA) were spiked in triplicate, extracted, and analyzed as separate 
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samples. The following compound concentrations were tested: 18,000 ng/mL for ampicillin, 
piperacillin, and tazobactam; 6,000 ng/mL for meropenem and acyclovir; and 3,000 ng/mL 
for metronidazole. Calculated concentrations for each extracted lot were compared to 
theoretical concentrations. In addition, the method's specificity was tested by screening the 7 
different human blank plasma lots for drugs and internal standard.  
 
Accuracy, precision, and recovery (extraction efficiency) 
 Accuracy and precision of the analytical method was quantified using 4 
concentrations of QC samples (including LLOQ) run 6 times (6 separate extractions) in 
sequence on 5 different days (total of 30 replicates for each concentration). In addition, 
accuracy and precision of diluted samples were determined. Dilutions (1:1, 1:3, and 1:9 
ratios) of a highly concentrated solution (300,000 ng/mL for ampicillin, piperacillin, and 
tazobactam; 100,000 ng/mL for meropenem and acyclovir; and 50,000 ng/mL for 
metronidazole) were performed with human plasma. The calculated concentrations were 
compared to the nominal concentrations.  
 Recovery (extraction efficiency) of the 6 compounds was determined with QC 
samples (all 3 QC concentration levels) by dividing the peak area of the extracted spiked 
plasma samples with the peak area of a spiked blank plasma extract.  
 
Stability 
 To test stability, samples were left at room temperature for 24 hours prior to 
extraction. Stability during sample handling was also verified by subjecting samples to either 
3 freeze-thaw cycles or storage for 24 hours in the refrigerator at 4° C prior to extraction. QC 
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samples at the 3 concentrations were used for this purpose. Also, stability in the autosampler 
for 24 hours was tested. One-month stability was tested by storing aliquots of QC samples for 




 The calibration curve was calculated using peak area ratio values at 7 standard 
concentrations. A quadratic regression provided the best fit to the data. The data for the 
calibration curves (n=5) are shown in Table 1.3, along with the mean ± standard deviation of 
5 standard curve quadratic coefficients, slopes, intercepts, and correlation coefficients (r2). 
The regression coefficient (r2) for all calibration curves was greater than 0.9965. Due to day-
to-day variations in the coefficients of the quadratic equation, standards and QCs should be 
generated for each day of analysis.  
 
Matrix effect 
 The percent difference from theoretical concentrations for all analytes was less than 
15%, except for acyclovir (21% difference, lot #1) and meropenem (26% difference, lot #3) 
(Table 1.4). Therefore, the extraction method was suitable for all analytes spiked in these 
matrices, except for the lots mentioned above. In addition, no response in MS/MS channels 






The limit of quantification 
 The LLOQ for ampicillin, piperacillin, tazobactam, metronidazole, meropenem, and 
acyclovir were 300, 300, 150, 50, 100, and 100 ng/mL, respectively, and the ULOQ for 
ampicillin, piperacillin, tazobactam, metronidazole, meropenem, and acyclovir were 150,000, 
150,000, 75,000, 25,000, 50,000, and 50,000 ng/mL, respectively. Chromatograms of blank, 
LLOQ, and ULOQ samples are shown in Fig. 1.1 and Fig. 1.2. 
 
Accuracy, precision, and recovery 
 The results of the accuracy and precision experiments at 4 different quality control 
levels are shown in Table 1.5. Within-day accuracy of all analytes ranged from 85–110%, 
with a mean of 101%. Between-day accuracy of all analytes ranged from 92–110%, with a 
mean of 101%. Within- and between-day coefficient of variations varied from 2.1–11.4%, 
and 4.0–9.1%, respectively. Overall, results indicate that the method was accurate and 
precise for each compound. In addition, concentration measurements of partially diluted 
samples were accurate and precise across all dilution ratios. The greatest percent deviation 
for all diluted samples was 16.8% for metronidazole when diluted 1:9. The greatest percent 
coefficient of variation for all the diluted samples was 14.1%. The absolute recovery of all 
compounds at all concentrations was greater than 75% (Table 1.3). 
 
Stability 
 Overall, each compound was stable under most tested conditions, with a few 
exceptions. After 24 hours at room temperature, all compound concentrations were within 
15% of nominal, with the exception of tazobactam (82% of nominal), piperacillin (75%), and 
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meropenem (84%). In 3 freeze-thaw cycles, on average all compound concentrations were 
within 10% of nominal. The low QC for ampicillin deviated 16% from nominal. All 
compounds were stable when left in the autosampler for 24 hours at 8° C (within 12% of 
nominal concentration), and all compounds were stable when left in the refrigerator (4o C) for 
24 hours, being within 13% of the nominal concentration. In addition, after 1 month of 
storage at <70o C, all compounds were within 15% of controls. 
 
Analysis of patient samples 
 We evaluated the applicability of the described method by analyzing sparse plasma 
samples collected from premature infants (<32 weeks gestational age at birth, N=8) given 
multiple intravenous doses of piperacillin-tazobactam (Table 1.6). Piperacillin and 
tazobactam were found in almost all patient samples. The mean (standard deviation [SD]) 
estimated gestational age at birth, postnatal age, and birth weight were 25 (2.7) weeks, 7 (7) 
days, and 728 (185) grams, respectively. The overall mean (SD) piperacillin concentration 
was 41,123 (53,789) ng/mL; the mean (SD) piperacillin concentration in infants < and ≥ 28 
weeks postmenstrual age were 45,159 (58,686, n=6) and 24,310 (20,186, n=2) ng/mL, 
respectively. In addition to piperacillin and tazobactam, ampicillin was found in 5 patients, 
metronidazole in 3 patients, and acyclovir in 1 patient. Meropenem was not found in any of 
the samples. Dosing of these agents could be confirmed in 7/8 patients. 
 
Discussion  
 The method described in this report measures drug concentration of 6 antimicrobials 
accurately and precisely in micro-volumes (50 µL) of plasma. Previous investigators have 
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developed analytical methods to measure drug concentrations of antimicrobials in low 
plasma volumes; however, most involve antimicrobials of the same drug class and no 
antivirals.4 The ability to simultaneously measure drug concentrations of antimicrobials from 
different classes, including antivirals, is an important milestone in evaluating drug 
disposition in premature infants. The latter is often challenging due to blood volume 
limitations in this population; therefore, drug concentration information obtained from each 
sample should be maximized. This can be accomplished with this assay as premature infants 
are often treated with several antimicrobials simultaneously. This is evidenced in the patient 
samples tested, as acyclovir and metronidazole were found in some of the infants treated with 
piperacillin-tazobactam. A high degree of variability and a trend towards decreasing 
piperacillin concentrations was observed with increasing postmenstrual age. Even though it is 
not possible to perform formal statistical inferences to assess significance of piperacillin 
concentration differences between postmenstrual age groups, it is likely that these differences 
result from maturational changes characteristic of the developing infant. These 
developmental changes are often related to improvement in renal function that leads to 
increased piperacillin clearance. This observation has been demonstrated in previous studies 
evaluating the PK of piperacillin in more mature premature infants.9 A formal population PK 
analysis is underway to quantify and identify sources of variability in piperacillin 
concentrations in this population. 
 In addition to the advantages offered by micro-volumes and multiplex methodologies 
in premature infant studies, dried blood spot (DBS) sampling is becoming an attractive 
technology for use in this population. This technology requires minimum amounts of whole 
blood per sample (<30 µL), virtually no sample processing, and convenient room 
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temperature storage. Even though several bioanalytical assays have been developed using 
DBS technology, only 1 clinical study has evaluated the use of DBS in premature infants.10 
The utility of this technology across therapeutics in this population remains to be determined.  
 The extraction process (protein precipitation) used for this method has been 
previously described for beta-lactam antibiotics.4 In the present method, this simple and 
straightforward extraction process provided excellent recovery (>90%) for most compounds. 
It is possible that the compounds with the lowest extraction efficiency (77–83%), meropenem 
and acyclovir, remained trapped in the protein precipitate or did not completely dissolve into 
the organic phase. In spite of this limitation, the extraction procedure used in this method 
provides a high level of efficiency in sample preparation, as well as high throughput 
processing of patient samples.  
 Although clinical plasma samples >50 µL from premature infants can be obtained, it 
is not without difficulty. This assay was designed to use sample volumes as low as 5 µL, 
which holds a number of advantages. Samples requiring repeat analysis can be diluted (1:1, 
1:3, or 1:9) with blank plasma and extracted. This is particularly advantageous for 
concentrations >ULOQ that need to be diluted back into the curve. Samples known to 
contain beta-lactams (tazobactam, piperacillin, meropenem) should be handled carefully 
given the lack of stability of these compounds at room temperature. Freeze-thaw cycles, 
however, did not affect the stability of any of the compounds, which allows for retesting of 
samples if needed.  
 We successfully developed a method to simultaneously assay ampicillin, piperacillin, 
tazobactam, meropenem, acyclovir, and metronidazole in human plasma. The assay has been 
validated with respect to accuracy, precision, limit of detection, recovery, and stability 
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(except as noted). The assay has been successfully applied to clinical samples from 
premature infants. This method has many clinical applications within the field of pediatrics, 






1. Stoll BJ, Hansen N, Fanaroff SS, et al. Late-onset sepsis in very low birth weight 
neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 
2002;110 (2 Pt 1):285–291. 
 
2. Stoll BJ, Hansen NI, Higgins RD, et al. Very low birth weight preterm infants with early 
onset neonatal sepsis: the predominance of gram-negative infections continues in the 
National Institute of Child Health and Human Development Neonatal Research Network, 
2002–2003. Pediatr Infect Dis J. 2005;24(7):635–639. 
 
3. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the 
neonatal intensive care unit: data from a large national data set. Pediatrics. 
2006;117(6):1979–1987. 
 
4. Ahsman MJ, Wildschut ED, Tibboel D, Mathot RA. Microanalysis of beta-lactam 
antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. 
Antimicrob Agents Chemother. 2009;53(1):75–80. 
 
5. Jung BH, Rezk NL, Bridges AS, Corbett AH, Kashuba AD. Simultaneous determination 
of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid 
chromatography-tandem mass spectrometry. Biomed Chromatogr. 2007;21(10):1095–
1104. 
 
6. Denooz R, Charlier C. Simultaneous determination of five beta-lactam antibiotics 
(cefepim, ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by high-
performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt 
Technol Biomed Life Sci. 2008;864(1-2):161–167. 
 
7. Holt DE, de Louvois J, Hurley R, Harvey D. A high performance liquid chromatography 
system for the simultaneous assay of some antibiotics commonly found in combination in 
clinical samples. J Antimicrob Chemother. 1990;26(1):107–115. 
 
8. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation--a revisit with a 
decade of progress. Pharm Res. 2000;17(12):1551–1557. 
 
9. Kacet N, Roussel-Delvallez M, Gremillet C, Dubos JP, Storme L, Lequien P. 
Pharmacokinetic study of piperacillin in newborns relating to gestational and postnatal 
age. Pediatr Infect Dis J. 1992;11(5):365–369. 
 
10. Suyagh M, Collier PS, Millership JS, et al. Metronidazole population pharmacokinetics 












Ampicillin 15 16.0 1 
Piperacillin 15 15.7 1 
Tazobactam 15 16.2 1 
Meropenem 5 5.8 1 
Acyclovir 5 5.0  1 
Metronidazole 2.5 2.5 1 
 





















Ampicillin 349.40 Positive 350.1 160.1 10 20 
Piperacillin 517.55 Positive 518.2 143.2 10 25 
Tazobactam 300.29 Negative 299.0 137.9 10 -20 
Meropenem 383.46 Positive 384.1 141.1 10 25 
Acyclovir 225.20 Positive 226.1 152.1 10 18 
Metronidazole 171.153 Positive 172.1 128.1 10 20 
Dicloxacillin 
(IS) 470.32 Positive 470.1 160.1  10  
20 
Dicloxacillin 
(IS) 470.32 Negative 468.0 326.8 10 
-20 
 
























Lot # 1 2 3 4 5 1 2 




20,567 18,833 20,133 19,367 18,567 18,533 17,833 
% deviation 14.26 4.63 11.85 7.59 3.15 2.96 -0.93 




18,733 17,667 18,333 17,733 19,567 17,633 17,467 
% deviation 4.07 -1.85 1.85 -1.48 8.70 -2.04 -2.96 




18,133 18,933 18,300 19,000 17,767 17,500 18,133 
% deviation 0.74 5.19 1.67 5.56 -1.30 -2.78 0.74 




6,722 5,989 7,533 6,233 6,353 5,511 5,756 
% deviation 12.04 -0.19 25.56 3.89 5.89 -8.15 -4.07 




7,289 6,089 6,756 6,189 6,927 6,444 6,056 
% deviation 21.48 1.48 12.59 3.15 15.44 7.41 0.93 
Metronidazole        




















Lot # 1 2 3 4 5 1 2 
concentration 
(ng/mL) 
% deviation 8.70 7.59 7.41 4.81 8.33 2.96 0.37 
 





Table 1.5. Summary of accuracy and precision 
   Intra-assay Inter-assay 
Compound Concentration 
(ng/mL) 
Accuracy (%) CV (%) Accuracy 
(%) 
CV (%) 
Ampicillin 300 100.33 4.36 101.49 6.18 
  900 96.29 5.20 95.37 6.97 
  60,000 107.01 2.85 106.62 3.98 
  120,000 98.00 4.03 98.19 5.26 
Piperacillin 300 107.69 2.99 107.94 6.35 
  900 99.00 5.43 99.54 6.49 
  60,000 102.82 3.72 103.82 5.65 
  120,000 100.64 7.04 101.25 8.20 
Tazobactam 150 98.09 4.63 99.16 6.75 
  450 110.39 4.32 109.53 5.38 
  18,000 104.24 2.63 104.54 5.42 
  60,000 99.71 2.29 99.66 7.02 
Meropenem 100 101.96 5.40 103.23 7.81 
  300 94.10 5.91 94.99 7.50 
  20,000 107.59 3.22 107.63 4.22 
  40,000 99.22 4.65 99.58 6.07 
Acyclovir 100 100.78 5.73 100.31 9.06 
  300 92.17 5.51 92.43 7.96 
  20,000 92.64 4.31 92.72 6.01 
  40,000 92.03 6.88 93.44 8.50 
Metronidazole 50 102.78 8.42 101.29 9.44 
  150 95.24 6.64 96.05 7.73 
  10,000 106.31 4.03 107.10 6.11 
  20,000 100.08 4.09 100.08 6.62 
Mean  100.38 4.76 100.67 6.70 
 
CV: coefficient of variation.
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1 1 28200 1260 346 BLD BLD BLD 
1 2 49850 2725 BLD BLD BLD BLD 
1 3 48000 2820 438 BLD BLD BLD 
2 1 24300 2730 BLD BLD BLD BLD 
2 2 53400 6800 BLQ BLD BLD BLD 
3 1 42600 7290 55400 BLD BLD BLD 
4 1 52000 16200 3330 BLD BLD 13700 
4 2 47300 11900 23100 BLD BLD 21800 
4 3 BLD BLD BLQ BLD BLD BLD 
4 4 BLD BLD BLD BLD BLD BLD 
4 5 32750 6450 BLD BLD BLD 7050 
4 6 85600 15480 602 BLD BLD 8000 
4 7 37500 7720 BLD BLD BLD 1060 
5 1 3640 BLQ BLQ BLQ BLD BLD 
5 2 4920 BLQ BLQ BLD BLD 352 
5 3 17000 851 BLQ BLD BLD 87.3 
6 1 78100 10300 374000 BLD BLD BLD 
6 2 286000 19900 367000 BLD BLD BLD 
6 3 64400 11400 532000 BLQ BLD BLD 
7 1 69900 8760 145000 BLD BLD BLD 
7 2 111000 10400 78800 BLQ BLD BLD 
7 3 54400 6360 355000 BLD BLD BLD 
7 4 20900 2450 88600 BLD BLD BLD 
7 5 18100 2740 460000 BLD BLD BLD 
7 6 11850 BLD 94000 BLD BLD BLD 
7 7 6760 1250 427000 BLD BLD BLD 
8 1 6990 BLQ BLD BLD 51800 BLD 
8 2 1890 BLD BLD BLD 9140 BLD 
8 3 1940 BLD BLD BLD 85300 BLD 



















8 5 5760 BLD BLD BLD 21900 BLD 
8 6 7490 BLQ BLD BLD 35500 BLD 
8 7 BLD BLD BLD BLD 10100 BLD 
8 8 BLQ BLD BLD BLD 3110 BLD 
8 9 BLQ BLD BLD BLD 1310 79.2 
8 10 460 BLD BLD BLD 1200 91.4 
 




Fig. 1.1. Blank plasma sample run in a) negative (tazobactam) and b) positive (top to bottom: 













Fig. 1.2. Lower limit of quantification in a) negative (top to bottom: tazobactam and 
dicloxacillin [IS]) and b) positive (top to bottom: dicloxacillin [IS], metronidazole, acyclovir, 
ampicillin, meropenem, piperacillin) ionization mode. Upper limit of quantification in c) 
negative (top to bottom: tazobactam and dicloxacillin [IS]) and d) positive (top to bottom: 
dicloxacillin [IS], metronidazole, acyclovir, ampicillin, meropenem, piperacillin) ionization 























CHAPTER II: POPULATION PHARMACOKINETICS OF PIPERACILLIN USING 
SCAVENGED SAMPLES FROM PRETERM INFANTS  
 
Introduction 
 Piperacillin is a semisynthetic derivative of ampicillin with a ureido and piperazine 
side chain.1 The combination of piperacillin with tazobactam (beta-lactamase inhibitor) is 
approved by the U.S. Food and Drug Administration (FDA) for the treatment of children >2 
months of age with appendicitis or peritonitis. The European Medicines Agency has 
approved the combination for the treatment of complicated intra-abdominal infections in 
children 2–12 years of age. Safety, efficacy, and dosing recommendations for infants <2 
month of age have not been established. In adults and older children, more than 70% of 
piperacillin is primarily excreted unchanged in the urine. Total body clearance increases and 
elimination half-life decreases with increasing age.2,3 After intravenous administration, the 
elimination half-life of piperacillin in adults and children 2–12 years of age is short (0.5–1 
hour); elimination half-life is prolonged in children and infants <23 months of age (0.9–1.4 
hours).2,3  
 In infants <2 months of age, piperacillin-tazobactam is commonly used “off label” for 
the treatment of intra-abdominal infections, such as necrotizing enterocolitis, as well as 
severe infections due to bacterial resistance. Appropriate dosing recommendations for this 
population have been limited by single-center studies and exclusion of the most preterm (<28 
weeks gestational age at birth) infants.4 Because the main clearance mechanism for 
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piperacillin is the renal system, ontogenic pharmacokinetic (PK) changes in the developing 
infant are expected. Extrapolation of PK data from more mature infants is often difficult due 
to non-linear relationships between maturation and renal function.5 PK studies are needed in 
preterm infants to appropriately describe drug disposition in this population.  
PK studies are rarely conducted in infants due to the research challenges posed by this 
population in the context of traditional study design. These challenges include limited blood 
volume for PK sampling, difficulty in obtaining PK samples due to the critical medical 
condition of the infants, and low parental informed consent rates. As such, investigators have 
explored novel minimal-risk methods to evaluate the PK of antimicrobials in this population. 
One approach is the use of scavenged samples, left over from the normal clinical care of 
infants. When combined with the collection of timed PK samples (collected specifically for 
study purposes), scavenged samples have allowed for characterization of the PK in preterm 
infants.6 To our knowledge, the use of scavenged samples for PK analysis of other 
antimicrobials has not been evaluated. The present study was conducted to assess the 
population PK of intravenous piperacillin using scavenged samples collected from preterm 




 Pharmacokinetic samples for this analysis were obtained from the Antimicrobial PK 
in High-Risk Infants trial sponsored by the Pediatric Pharmacology Research Unit. This 
multi-center, prospective, open-label PK study of commonly used antimicrobial agents in the 
neonatal intensive care unit enrolled infants ≤32 weeks gestational age at birth who were 
40 
 
<120 days old and who were receiving intravenous piperacillin or piperacillin-tazobactam 
per routine medical care. Piperacillin dosing was determined by the routine clinical practice 
in each unit, and no exclusion criteria were used. Infants were stratified by birth gestational 
age (BGA) at enrollment: <26 weeks, 26–29 weeks, and 30–32 weeks. The study was 
approved by the institutional review boards at each institution, and informed consent was 
obtained prior to enrollment. 
 The following information was collected for covariate analysis: BGA, postnatal age 
(PNA), postmenstrual age (PMA), weight, sex, race, serum creatinine, and ethnicity. 
Covariates that exhibited time-dependent changes (e.g., weight, PNA) were permitted to 
change with time, and the actual value in the data set reflects the observations made at each 
patient visit. Missing weights were imputed with the last recorded value carried forward for 
up to 7 days. Serum creatinine (SCR) was recorded when obtained for clinical care. Missing 
SCR values were imputed based on an exponential model of SCR and PMA derived from the 
data.  
  
PK sample collection 
 A sparse sampling approach was followed in this study. Samples were divided into 2 
types: scavenged and blood draw. Scavenged samples were defined as samples obtained 
without obtaining additional blood from the infant. These samples were collected from the 
clinical laboratory from discarded blood (heparinized or ethylenediaminetetraacetic acid 
[EDTA] tubes) obtained for routine clinical care. Blood draw samples were defined as 
samples obtained with collection of extra blood from the infant. Each blood draw was 
approximately 0.3 mL of blood collected in EDTA Microtainers. PK sample collection was 
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planned at the following time points: immediately prior to piperacillin infusion, immediately 
after the completion of infusion (t=0), approximately 1 hour after completion of infusion (t=1 
hour), approximately 2 hours after completion of infusion (t=2 hours), and immediately prior 
to infusion of the next dose. The duration of piperacillin infusion was performed according to 
routine clinical care at the site. Samples were refrigerated or placed on ice immediately after 
collection and then centrifuged at 1500 g and 4o C for 10 minutes. Plasma was removed and 
stored at -70° C. Samples from all sites were shipped on dry ice to Duke University Medical 
Center where they were stored at -70° C prior to analysis. Samples were stored for a 
maximum of 32 months prior to analysis.  
  
Bioanalytical assay 
 A liquid chromatography-tandem mass spectrometry (HPLC/MS/MS) assay for 
piperacillin detection in human plasma suitable for small plasma volumes was developed and 
validated. Sample analysis was performed on a triple quadrupole mass spectrometer API 
4000 (Applied Biosystems–ABSciex, Foster City, CA, USA) operated with electrospray 
ionization (TurboV source using a TurboIonspray® probe). Instrument parameters were 
optimized for the piperacillin transition (518.2→143.2 m/z). Ionspray voltage and turbo 
heater temperature were kept at 2500 V and 500o C, respectively; a collision gas of 10 and a 
collision energy of 25 V were used. Piperacillin and dicloxacillin (internal standard [IS]) 
were purchased from the Sigma Chemical Company (St. Louis, MO, USA). HPLC separation 
was achieved using a reverse-phase C18 Aquasil column (Thermo Fisher, Waltham, MA, 
USA) with a flow-rate of 0.75 ml/min using a gradient mobile phase. Mobile phase A 
consisted of 0.1% formic acid in water, and mobile phase B consisted of 0.1% formic acid in 
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methanol. Total run time was 6 minutes. Analytical data were acquired by Analyst Software 
1.4.1 (Applied Biosystems–ABSciex, Foster City, CA, USA). The lower limit of quantitation 
of piperacillin in plasma was 0.3 mg/L. Intraday and interday coefficients of variation were 
<7% at concentrations ranging from 0.3–120 mg/L. 
  
Population PK analysis 
 PK data were analyzed with a nonlinear mixed effect modeling (NONMEM) 
approach using the computer program NONMEM (version 7) in conjunction with WINGS 
for NONMEM version 7.03 (Auckland, NZ). Output was summarized using STATA 10 
(College Station, TX, USA). The first-order conditional estimation method with interaction 
was used for all model runs. One- and 2-compartment structural PK models were evaluated. 
Inter-individual (IIV) random effects were evaluated on clearance (CL) and volume of 
distribution (V). Covariance was described by a block Omega matrix. An exponential model 
for IIV variance for CL and V was used, and a proportional error model was deemed 
appropriate to describe residual variability. The potential impact of clinical covariates on PK 
parameters was explored if a relationship was suggested by visual inspection of scatter and 
box plots (continuous and categorical variables, respectively) of individual Bayesian 
estimates obtained from the base model and IIV (ETAs) against covariates. The following 
covariates were evaluated: weight (kg), BGA (weeks), PNA (days), PMA (defined as BGA 
plus PNA in weeks [PNA/7]), SCR, race, sex, and ethnicity. Once covariates were identified 
during the model-building process, covariate testing was performed via standard forward 
addition backward elimination methods. Potential covariates that reduced the objective 
function by more than 3.84 (P<~0.05) were included in the subsequent multivariable 
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analysis. A forward inclusion with backwards elimination approach was used during the 
multivariable step, and a reduction of 6.63 (P<~0.01) was required for retention of a 
covariate in the final model. Continuous covariates were scaled to their median values. 
Empirical Bayesian estimates of individual infant PK parameters were generated from the 
final model using the post-hoc subroutine. 
  
Model evaluation 
 Models were evaluated based on successful minimization, goodness-of-fit plots, 
precision of parameter estimates, bootstrap procedures, and visual predictive check. The 
precision of the final population PK model parameter estimates was evaluated using 
parametric bootstrapping (1000 replicates) to generate the 95% confidence intervals (CIs) for 
parameter estimates. For the visual predictive check, the final model was used to generate 
1000 Monte Carlo simulation replicates of piperacillin exposure, and simulated results were 
compared with those observed in the study. The number of observed concentrations outside 
of the 90% prediction interval for each time point was quantified. 
  
Assessment of dose-exposure relationship 
 Piperacillin demonstrates time-dependent pharmacodynamics (PD). For target 
exposure, we chose the time above a minimum inhibitory concentration (MIC) of 16–64 
mg/L at steady state. This MIC target is consistent with the Clinical and Laboratory 
Standards Institute-recommended MIC susceptibility breakpoint of piperacillin/tazobactam 
for enteric gram-negative organisms such Escherichia coli and Enterobacter sp. (16 mg/L) 
and Pseudomonas aeruginosa (64 mg/L).7 Monte Carlo simulations using the final 
44 
 
population PK model were used to explore dose-exposure relationships using these defined 
targets. Commonly used and current piperacillin dosing recommendations listed in Neofax8 
and The Harriet Lane Handbook9 were used in these simulated datasets to evaluate target 
attainment rates at steady state. When a dosing range was recommended, the highest end of 
the range was chosen for the simulations. Target attainment rates were calculated for infants 
who achieved target piperacillin concentrations for 50% or 75% of the dosing interval. 
Inclusion of the more stringent PD target criteria (75% of the dosing interval) was derived 
from the assumption of an immuno-compromised state of preterm infants and the need to 




 A total of 77 subjects from 5 centers were evaluated for analysis. Subjects were 
excluded from the analysis if dosing, concentration, or sampling data were unreliable (i.e., 
unable to discern time when sample was collected relative to dose administered) (N=13) and 
if sampling was obtained during line flush or during drug infusion and no other samples were 
collected (N=8). The exclusion of these subjects and samples resulted in 56 subjects from 5 
sites with 211 concentrations used in the modeling process. The overall median (range) 
BGA, PNA, PMA, weight, SCR, and dose were 25 (22–32) weeks, 17 (1–77) days, 29 (23–
40) weeks, 867 (400–2580) g, 0.8 (0.2–2.4) mg/dL, and 88 (39–147) mg/kg, respectively 
(Table 2.1). The majority of subjects were male (31/56, 56%) and white (29/56, 52%), and 





 A total of 41/261 (16%) outlier drug concentrations were removed from the analysis 
due to unreliability of sampling times related to time of infusion (N=18), time of flush 
(N=20), or sample contamination (N=3). Six of these samples did not have any measurable 
piperacillin concentrations. The median time of PK sampling was 4.7 (0–11.16) hours after 
the dose, and the median concentration was 25.6 (0.041–502) mg/L. An average of 3.7 
samples per infant (range, 1–22) was collected, and the overwhelming majority of PK 
samples were scavenged from the clinical laboratory (202/211, 96%). Sixteen samples 
(16/211, 7.6%) had concentrations below the limit of quantitation; 6/211 (2.8%) had a 
reliable signal above background noise documented on the LC/MS/MS instrument, and this 
measurement was used in the PK analysis. A value of zero was assigned to the remaining 
samples (10/211 [4.7%]) as they were below the level of detection.  
  
Population PK model building 
 A 1-compartment model was the appropriate structural PK model for this data set 
(Fig. 2.2). Because few samples were obtained within the first few hours post dose, it was not 
possible to estimate inter-compartmental clearance, and a 2-compartment model did not 
provide a better fit to the data. Weight was included in the base CL and V models (Table 
2.2). Allometric scaling (Weight0.75) as well as estimation of the body size exponent 
(Weightθ) were explored as potential body size models for CL and V. The exponent estimates 
for CL and V were 0.62 and 0.86, respectively. However, given strong physiologic basis and 
no improvement in model fit, exponents for weight were fixed at 0.75 and 1 for CL and V, 
respectively. In the base model, scatter plots showed a correlation between IIV on CL 
46 
 
(ETA1) and V (ETA2); a covariance term was added to the model. Age- and maturity-related 
covariates (BGA, PMA, PNA), as well as SCR, showed correlation with unexplained CL 
(ETA1) IIV (Fig. 2.1). During the univariable evaluation (after inclusion of body weight), all 
age-related covariates resulted in a significant decrease in the objective function value 
(OFV); however, the largest drop in OFV occurred when SCR was added to the model (Table 
2.2). A SCR power model with exponent estimation did not improve the goodness of fit. CL 
estimated by SCR was superior to age-related models, and the addition of a maturation 
covariate (PMA) in the multivariable analysis did not improve the model goodness of fit 
(Tables 2.2 and 2.3). No other covariates were evaluated in the V model due to lack of 
correlation observed between the covariate and unexplained V (ETA2) IIV. Due to the low 
number of blood draw samples, bias introduced by scavenged specimen collection compared 
with timed blood draws around the dose could not be assessed. 
  
Population PK model evaluation 
 The final model had good precision as evidenced by relative standard errors around 
the parameter point estimates of 13.7–32.2% and by 95% confidence intervals generated by 
bootstrapping (N=1000 simulated trials, 981 successful runs) (Table 2.3). Larger relative 
standard errors were observed for the point estimates of V. Goodness-of-fit diagnostic plots 
for the final model are shown in Fig. 2.2. The visual predictive check revealed a good fit 
between observed and predicted piperacillin concentrations (Fig. 2.3). Only 8.5% (18/211) of 





Bayesian estimates of CL, V, and elimination half-life 
 The median individual empirical Bayesian estimates for CL, V, and half-life were 
summarized by gestational age group (Table 2.4). There was a trend towards increasing 
median piperacillin weight-normalized CL with increasing BGA that was more apparent 
between infants <26 weeks BGA and infants 26–29 weeks BGA. Weight-adjusted 
piperacillin CL decreased with increasing SCR and, expectedly, did not change with 
increasing body weight (Fig. 2.4). Infants with SCR ≥1.2 mg/dL had a 60% lower CL value. 
Half-life decreased with increasing BGA group. 
  
Dose-exposure relationship 
 High failure rates were calculated when the surrogate PD targets of time above MIC 
of 16 and 64 mg/L for 50% and 75% of the dosing interval were evaluated. Only 60% of all 
infants achieved piperacillin concentrations >16 mg/L for 50% of the dosing interval. Only 
30% of infants ≤29 weeks and none of those 30–32 weeks BGA achieved piperacillin 
concentrations >64 mg/L for 50% of the dosing interval (Fig. 2.5). When the same targets 
were evaluated for 75% of the dosing interval, 50% of all infants achieved piperacillin 
concentrations >16 mg/L; 15% of infants ≤29 weeks and none of those 30–32 weeks BGA 
achieved piperacillin concentrations >64 mg/L for 75% of the dosing interval. Monte Carlo 
simulations using the final population PK model were used to explore dose-exposure 
relationships using current piperacillin dosing recommendations. Overall, dosing 
recommendations by Neofax (100 mg/kg every 8–12 hours) and The Harriet Lane Handbook 
(75 mg/kg every 8–12 hours) produced similar piperacillin exposures in simulated datasets; 
only 40–60% of infants across BGA achieved the PD target of concentrations above 16 mg/L 
48 
 
for 50% of the dosing interval. Piperacillin concentrations >64 mg/L for 75% of the dosing 
interval were achieved in the minority of simulated patients (<25%); this finding was most 
pronounced among infants 30–32 weeks BGA (Fig. 2.5).  
 
Discussion 
Most antimicrobial products used in preterm infants lack some aspect of PK 
information specific to this population. Without appropriate studies specifically designed for 
preterm infants, clinicians are often forced to prescribe products “off-label,” exposing 
patients to potential adverse drug effects or less-than-optimal drug exposure without dosing 
evidence.10,11  
The primary goal was to evaluate the PK of piperacillin in this population, evaluate 
potential covariates that would explain inter-individual variability in PK parameters, and 
assess the potential bias introduced by scavenged sampling compared with traditional 
sampling per study protocol. A population PK approach allowed for the use of sparse 
sampling, and stratified enrollment ensured a broad distribution of BGA and PNA.  
In the present model, piperacillin CL increased with allometrically scaled body 
weight, and it decreased proportionally with increasing SCR. Allometric size adjustments in 
PK parameters have been well established as appropriate and physiologic-based models to 
describe CL changes among neonates and preterm infants.6,12 The association of CL with 
SCR is expected due to the high proportion (>70%) of piperacillin excreted in the urine.3 
However, the clinical utility of SCR in preterm infants during the first few days of life is 
debated due to the confounding effect of maternal creatinine. Because only 3 (5%) of 
subjects in this study were <3 days of life, it is unlikely that bias was introduced by maternal 
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creatinine contamination. The addition of maturational components (i.e., BGA, PNA, PMA) 
into the multivariable CL model did not change the goodness of fit nor did it explain 
remaining IIV. Due to ontogenic changes in renal function among preterm infants, SCR is 
strongly linked with maturational components such as BGA, PNA, and PMA. A correlation 
matrix between covariates included in this study revealed this association. This observation 
likely prevented the ability to discern the effect of each maturational component in CL IIV 
from SCR in the CL model-building process. Weight was the only covariate that explained V 
IIV, consistent with other studies in preterm infants.12  
The population PK model developed performed well and showed good precision 
around parameter estimates. A high degree of IIV in CL (91.5% coefficient of variation 
[CV]), V (119 CV%), and residual variability (RV, 73.8 CV%) was observed. The large IIV 
in CL and V could have resulted from the diversity of study subjects included in this trial. 
However, large unexplained IIV in CL and V remained in the final model after inclusion of 
significant covariates. Because study efficiency was an important part of the study design, 
data collection (demographics and other clinically relevant covariates) was limited. The 
unexplained IIV could be attributed to other covariates not included in the study (i.e., 
concomitant medications). The large RV observed could be the result of several factors, such 
as documentation errors in sampling or dosing times, model misspecification, and drug 
degradation in scavenged samples. Ambient and refrigerator storage may affect piperacillin 
stability in plasma.13,14 Information regarding the duration and conditions under which the 
samples remained in the clinical laboratory before freezing were not collected, which limits 
our ability to assess the reliability of drug concentrations in scavenged samples. Because very 
few samples were drawn specifically for the study, the comparison between traditional and 
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scavenged sampling schemes was not possible. Large RV was unlikely to be the result of 
drug concentration measurements given that the assay was validated according to FDA 
criteria.15 
Because this study did not evaluate efficacy or clinical outcomes, surrogate 
piperacillin PD end points were used for the study population receiving piperacillin per 
routine clinical care and in simulated datasets including current dosing recommendations 
from commonly used pediatric resources.8,9 The proportion of patients achieving surrogate 
PD targets for efficacy was suboptimal. A substantial proportion of subjects (~40%) did not 
achieve piperacillin concentrations efficacious against common gram-negative enteric 
bacteria (i.e. Escherichia coli, enterobacter), and the vast majority (~70%) did not achieve 
concentrations above the susceptibility breakpoint for more resistant organisms such as 
Pseudomonas aeruginosa. A similar pattern was observed among simulated datasets using 
current dosing recommendation guidelines. Dosing by Neofax or The Harriet Lane 
Handbook resulted in similar target attainment rates, but similar to targets in the actual 
patient population, outcomes were suboptimal. These findings could suggest that current 
dosing per standard of care or as recommended in common pediatric resources is inadequate 
for this patient population. However, this should be interpreted with caution because lower 
(2–10-fold) than previously observed piperacillin concentrations2,4 were observed in this 
study, possibly as a result of scavenged sampling. 
Our understanding of the PK of piperacillin in preterm infants is extremely limited. A 
single-center, single-dose PK study of piperacillin (75 mg/kg) conducted in 28 newborn 
infants with BGA of 29–40 weeks and PNA of 3–11 days demonstrated an increase in 
clearance with increasing gestational age.4 This study, however, excluded neonates <28 
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weeks estimated gestational age and infants beyond the second week of life. It is therefore 
difficult to compare our study results to this prior study, but overall the individual empirical 
Bayesian CL and V estimates of the present study were higher (2–10-fold) than previously 
reported after controlling for BGA and PMA. V estimates were particularly large when 
compared with other patient populations including older infants and adults.2,3 A large 
piperacillin V would be expected in preterm infants due to the high total water content 
relative to body mass16 and the hydrophilic nature of the drug. Alternatively, higher than 
expected CL and V estimates are likely the result of low piperacillin concentrations 
encountered in this trial. As mentioned, drug degradation in scavenged samples may have 
accounted for the low concentrations observed. 
In summary, minimal-risk methods such as scavenged PK sampling can provide 
meaningful information related to development of structural PK models, as well as potential 
covariates that explain IIV in PK parameters. After allometric scaling, incorporating SCR as 
a CL model increased the model fit, and dose adjustments will likely be needed based on this 
parameter. The utility of scavenged sampling in providing dosing recommendations, 
however, is drug-dependent and likely not useful for unstable drugs such as piperacillin 
without stringent criteria regarding handling or documentation of handling to eliminate 
degraded samples from analysis. Future efforts evaluating this methodology should consider 
the physicochemical properties of the drug, more detailed documentation of sample 
collection and storage conditions, and simultaneous collection of traditional plasma samples 
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Table 2.1. Clinical data by gestational age group 
Characteristic 
Gestational age at birth (weeks) 
<26 26–29 30–32 
N 29 20 7 
Gestational age, 
weeks 24 (22, 25) 27 (26, 29) 31 (28, 32) 
Postnatal age, days 17 (1, 77) 15 (1, 75) 24 (3, 65) 
Postmenstrual age, 
weeks 27 (23, 35) 30 (27, 38) 35 (31, 40) 
Weight, g 709 (400, 1400) 1023 (555, 2580) 1610 (1357, 1890) 
Female sex 14 (48) 5 (25) 6 (86) 
Race       
White 15 (52) 10 (50) 4 (57) 
Black 12 (41) 9 (45) 2 (29) 
Other 2 (7) 1 (5) 1 (14) 
Hispanic 2 (7) 1 (5) 2 (29) 
Serum creatinine 
(mg/dL) 1 (0.3, 2.4) 0.8 (0.2,2) 0.5 (0.2,0.9) 
Dose (mg/kg) 80 (43,147) 87 (44,116) 100 (39,110) 
Dosing frequency 
(h) 8 (6,14) 8 (6,13) 8 (6,16) 
 






Table 2.2. Model-building process 
Base model and 
univariable 
analysis Population model OFV ΔOFV 
V V = θV X (wt)1 1653 - 
CL base model CL = θCL X (wt)0.75 1653 - 
BGA CL = θCL X (wt)0.75 X (BGA/25)θCL-BGA 1647 -6 
PMA CL = θCL X (wt)0.75 X (PMA/29)θCL-PMA 1643 -10 
PNA CL = θCL X (wt)0.75 X (PNA/17)θCL-PNA 1645 -8 
SCR CL = θCL X (wt)0.75 X (0.5/SCR) 1618 -35 
Multivariable 
model       
CL, PMA, and 
SCR CL = θCL X (wt)0.75 X (0.5/SCR) X (PMA/29)θCL-PMA 
1618 0 
 
V: volume of distribution; CL: clearance; BGA: gestational age at birth; PMA: postmenstrual 
age; PNA: postnatal age; SCR: serum creatinine (mg/dL); wt: weight; OFV: objective 
















Parameter 2.5% Median 97.5% 
CL (L/h) θCL 0.479 13.7 0.352 0.466 0.606 
V (L) θv 2.91 30.8 1.640 2.935 5.615 
              
Inter-individual 
variance             
CL (CV%) ω2CL  91.54 19.5 83.86 94.88 103.87 
V (CV%) ω2V  119.16 32.2 88.39 108.54 124.14 
CL vs. V correlation ω2CL-V  1.03 21.5 0.94 0.98 1.00 
              
Residual variance 
(CV%) σ2 73.82 13.7 79.25 85.56 91.27 
 
CL: clearance; V: volume of distribution; CV: coefficient of variation; CI: confidence 











Fig. 2.1. Base model scatter plots of CL ETA1 estimates and the following: BGA (A), PNA 






Fig. 2.2. Final population pharmacokinetic model diagnostic plots: observed vs. population 
prediction (A) and individual prediction (B), weighted residuals vs. population predictions 
(C) and time (D). For A and B, the line of identity is included as a reference. For weighted 






Fig. 2.3. Visual predictive check of piperacillin dose-normalized concentrations versus time. 
Solid black circles represent observed concentrations. Shaded gray area represents the 90% 








Fig. 2.4. Weight-normalized piperacillin clearance versus serum creatinine (A) and body 







Fig. 2.5. Pharmacodynamic target attainment rates by gestational age group. A: Proportion of 
patients who met PD target of desired concentrations for 50% of the dosing interval (black 
bar: 16 mg/L, gray bar: 64 mg/L); B: Proportion of patients who met PD target of desired 
concentrations for 75% of the dosing interval (black bar: 16 mg/L, gray bar: 64 mg/L); C: 
Proportion of simulated patients who met PD target of desired concentrations for 50% of the 
dosing interval (dark blue bar: Neofax 16 mg/L, light blue bar: Neofax 64 mg/L, dark gray 
bar: The Harriet Lane Handbook 16 mg/L, light gray bar: The Harriet Lane Handbook 64 
mg/L); D: Proportion of simulated patients who met PD target of desired concentrations for 
75% of the dosing interval (dark blue bar: Neofax 16 mg/L, light blue bar: Neofax 64 mg/L, 
dark gray bar: The Harriet Lane Handbook 16 mg/L, light gray bar: The Harriet Lane 













CHAPTER III: POPULATION PHARMACOKINETICS OF METRONIDAZOLE USING 
SCAVENGED SAMPLES FROM PRETERM INFANTS 
 
Introduction  
 Preterm infant pharmacokinetic (PK) studies are exceptionally scarce due to the 
research challenges posed by this population, such as limited blood volume for PK sampling, 
difficulty in timing of PK samples due to the critical medical condition of the infants, 
difficult access to obtain samples, and low parental informed consent rates. Feasibility issues 
also are imposed by traditional PK study designs, which require large numbers of specifically 
timed PK blood samples. These difficulties have encouraged investigators to explore novel 
minimal-risk methods to evaluate the PK of antimicrobials in this population. One proposed 
method is the use of scavenged samples left over from the normal clinical care of infants. 
The use of scavenged samples for PK studies in preterm infants offers several advantages 
over traditional timed PK trials. These include avoiding the need for heel sticks specifically 
for the study; higher rates of parental consent due to perceived minimal risk; availability of 
several samples per infant; and avoidance of time-specific PK sampling.1 This methodology, 
combined with collection of timed PK samples (collected specifically for study purposes), 
has proven successful in the evaluation of fluconazole PK in preterm infants.1 To our 




Metronidazole is approved by the U.S. Food and Drug Administration for the 
treatment of adults with serious infections caused by susceptible anaerobic bacteria but is not 
approved for use in children. In spite of this, metronidazole is extensively used “off-label” in 
children to treat anaerobic intra-abdominal infections (i.e., perforated appendicitis).2 In 
young infants, its use is typically restricted to treatment of rare cases of anaerobic 
bacteremia, central nervous system infections, and complicated intra-abdominal infections 
such as necrotizing enterocolitis.3,4 Because infection in young infants with very low birth 
weight (<1500 g birth weight) is associated with devastating outcomes including death and 
neurodevelopmental impairment, appropriate dosing recommendations for agents such as 
metronidazole are needed in this population. 
Metronidazole dosing recommendations for preterm infants listed in commonly used 
reference sources for pediatric practitioners are based on a combination of birth weight and 
postnatal age (PNA)5 or birth gestational age (BGA) and postmenstrual age (PMA).6 These 
recommendations are derived from small, single-center studies and have not been 
prospectively evaluated. In addition, these dosing regimens are cumbersome due to the 
different combinations of maturation components required to choose the most appropriate 
dose. PMA-based dosing offers an advantage over current recommendations by simplifying 
dosing regimens and potentially providing desired metronidazole concentrations over a wider 
age range. PMA-based dosing has not been systematically evaluated for metronidazole; 
however, it has been proven successful for other therapeutics in preterm infants.7–9 
The present study was conducted to assess the population PK of intravenous 






 PK samples for this analysis were obtained from the Antimicrobial PK in High-Risk 
Infants trial sponsored by the Pediatric Pharmacology Research Unit (PPRU). This trial was a 
multi-center, prospective, open-label PK study of antimicrobial agents commonly used in the 
neonatal intensive care unit. Infants ≤32 weeks GA at birth and <120 days of age receiving 
intravenous metronidazole per routine medical care were enrolled. Metronidazole dosing was 
determined by the routine clinical practice in each unit, and no exclusion criteria were used. 
To evaluate the effect of maturation on metronidazole PK, infants were stratified at 
enrollment by GA: <26 weeks, 26–29 weeks, and 30–32 weeks. The study was approved by 
the institutional review boards at each institution, and informed consent was obtained from a 
parent or guardian prior to enrollment. 
 The following information was collected for covariate analysis: BGA, PNA, PMA, 
weight, sex, race, serum creatinine (SCR), and ethnicity. Covariates that exhibited time-
dependent changes (e.g., weight, PNA) were permitted to change with time, and the actual 
value in the data set reflects the observations made at each patient visit. Missing weights 
were imputed with the last recorded value carried forward for up to 7 days. SCR was 
recorded when obtained for clinical care. Missing SCR values were imputed based on an 
exponential model of SCR and PMA derived from the data.10 
  
PK sample collection 
 A sparse sampling approach was followed in this study. Samples were divided into 2 
types: scavenged and blood draw. Scavenged samples were defined as samples obtained 
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without obtaining additional blood from the infant. These samples were collected from the 
clinical laboratory from discarded blood (heparinized or ethylenediaminetetraacetic acid 
[EDTA] tubes) obtained for routine clinical care. Blood draw samples were defined as 
samples obtained with collection of extra blood from the infant. Each blood draw was 
approximately 0.3 mL of blood collected in EDTA Microtainers. PK sample collection was 
planned at the following time points: immediately prior to metronidazole infusion, 
immediately after the completion of infusion (t=0), approximately 1–1.5 hours after 
completion of infusion (t=1–1.5 hour), approximately 3–4 hours after completion of infusion 
(t=3–4 hours), and immediately prior to infusion of the next dose. The duration of 
metronidazole infusion was performed according to site routine clinical care. Samples were 
refrigerated or placed on ice immediately after collection and then centrifuged at 1500 g and 
4o C for 10 minutes. Plasma was removed and stored at -70° C. Samples from all sites were 
shipped on dry ice to Duke University Medical Center where they were stored at -70° C prior 
to analysis. Samples were stored for a maximum of 32 months prior to analysis.  
  
Bioanalytical assay 
 A liquid chromatography-tandem mass spectrometry (HPLC/MS/MS) assay for 
metronidazole detection in human plasma suitable for small plasma volumes was developed 
and validated.11 Briefly, sample analysis was performed on a triple quadrupole mass 
spectrometer API 4000 (Applied Biosystems–ABSciex, Foster City, CA, USA) operated with 
electrospray ionization (TurboV source using a TurboIonspray® probe). Instrument 
parameters were optimized for the metronidazole transition (172.1→128.1 m/z). HPLC 
separation was achieved using a reverse-phase C18 Aquasil column (Thermo Fisher, 
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Waltham, MA, USA) with a flow-rate of 0.75 ml/min using a gradient mobile phase. Mobile 
phase A consisted of 0.1% formic acid in water, and mobile phase B consisted of 0.1% 
formic acid in methanol. Analytical data were acquired by Analyst Software 1.4.1 (Applied 
Biosystems–ABSciex, Foster City, CA, USA). The lower limit of quantitation of 
metronidazole in plasma was 0.05 mg/L. Intraday and interday coefficients of variation were 
<9.5% at concentrations ranging from 0.05–25 mg/L. 
  
Population PK analysis 
 PK data were analyzed with a nonlinear mixed effect modeling (NONMEM) 
approach using the computer program NONMEM (version 7) in conjunction with WINGS 
for NONMEM version 7.03 (Auckland, NZ). Output was summarized using STATA 10 
(College Station, TX, USA). The first-order conditional estimation method with interaction 
was used for all model runs. One- and 2-compartment structural PK models were evaluated. 
Inter-individual (IIV) random effects were evaluated on clearance (CL) and volume of 
distribution (V). An exponential model for IIV variance was used, and a proportional error 
model was deemed appropriate to describe residual variability. The potential impact of 
clinical covariates on PK parameters was explored if a relationship was suggested by visual 
inspection of scatter and box plots (continuous and categorical variables, respectively) of 
individual Bayesian estimates obtained from the base model and CL IIV (ETA) against 
covariates. The following covariates were evaluated: weight (kg), BGA (weeks), PNA 
(days), PMA (defined as GA plus PNA in weeks [PNA/7]), SCR, race, sex, and ethnicity. An 
SCR model including an indicator variable (CR) that excluded a potential outlier with an 
SCR of 4.7 mg/dL was also evaluated. Once covariates were identified during the model-
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building process, covariate testing was performed via standard forward addition backward 
elimination methods. Potential covariates that reduced the objective function by more than 
3.84 (P<~0.05) were included in the subsequent multivariable analysis. A forward inclusion 
with backwards elimination approach was used during the multivariable step, and a reduction 
of 6.63 (P<~0.01) was required for retention of a covariate in the final model. Continuous 
covariates were scaled to their median values. Empirical Bayesian estimates of individual 
infant PK parameters were generated from the final model using the post-hoc subroutine. 
Bias introduced by scavenged specimens was evaluated in the random effects error model of 
the final population model using a fixed effect parameter (θSCAV), as well as different residual 
variability estimates for blood draws and scavenged samples. An indicator variable (SCAV) 
was used to identify scavenged samples (SCAV = 1).  
  
Model evaluation 
 Models were evaluated based on successful minimization, goodness-of-fit plots, 
precision of parameter estimates, bootstrap procedures, and visual predictive check. The 
precision of the final population PK model parameter estimates were evaluated using non-
parametric bootstrapping (1000 replicates) to generate the 95% confidence intervals (CIs) for 
parameter estimates. For the visual predictive check, the final model was used to generate 
1000 Monte Carlo simulation replicates of metronidazole exposure, and simulated results 
were compared with those observed in the study. The number of observed concentrations 





Assessment of dose-exposure relationship 
 Surrogate pharmacodynamic (PD) targets for metronidazole against anaerobic 
bacteria are poorly defined.12 Therefore, for target exposure, a minimum inhibitory 
concentration (MIC) of 8 mg/L at steady state was chosen as the surrogate efficacy target. 
This MIC target is consistent with the Clinical and Laboratory Standards Institute (CLSI)-
recommended MIC susceptibility breakpoint of metronidazole for anaerobic organisms.13 
Metronidazole trough concentrations at steady state were predicted for each subject using 
individual empirical Bayesian estimates from the final model and dosing prescribed in the 
study per routine medical care. The proportion of subjects in the study who met the PD target 
was calculated by GA group. In addition, Monte Carlo simulations (N=1000) using the final 
population PK model were used to explore dose-exposure relationships of commonly used 
metronidazole dosing recommendations listed in Neofax6 and The Harriet Lane Handbook,5 
as well as a newly proposed, more simplistic dosing regimen based on PMA (Table 3.1). 
When a dosing range was recommended, the highest end of the range was chosen for the 
simulations. The proportion of simulated subjects who met the PD target was calculated by 
GA group and PNA. Additionally, Monte Carlo simulations (N=100) using the final 
population PK model fixed and random effects estimates were performed to predict 
metronidazole concentrations in typical subjects receiving the newly proposed PMA-based 
dosing regimen including a loading dose. These typical subjects included an infant with PMA 
26 weeks (weight 900 g); 1 with PMA 32 weeks (weight 1900 g); 1 with PMA 36 weeks 







 Thirty-three subjects from 5 centers were evaluated for analysis. One subject was 
excluded from the analysis because sampling was obtained during drug infusion and no other 
samples were collected. The overall median (range) GA, PNA, PMA, weight, SCR, and dose 
were 27 (22–32) weeks, 41 (0–97) days, 32 (24–43) weeks, 1495 (678–3850) g, 0.5 (0.1–4.7) 
mg/dL, and 8 (4–15) mg/kg, respectively (Table 3.2). The majority of subjects were female 
(17/32 [53%]). Sixteen (50%) were white, and 4 (9%) were Hispanic. 
 
PK specimens 
 A total of 3/119 (2.5%) outlier concentrations were removed from the analysis due to 
unreliability of sampling times related to time of flush (N=2) or sample contamination (N=1). 
The exclusion of these subjects and samples resulted in 32 subjects from 5 sites with 116 
concentrations used in the modeling process. The median time of PK sampling was 6.5 (0.5–
24) hours after dose, and the median concentration was 14.5 (1.31–68.5) mg/L. An average 
of 3.6 samples per infant (range, 1–15) was collected, and the majority of PK samples were 
scavenged from the clinical laboratory (104/116, 90%).  
 
Population PK model building 
 A 1-compartment model was the appropriate structural PK model for this data set 
(Fig. 3.2). Because few samples were obtained within the first few hours post dose, inter-
compartmental clearance was not estimated and a 2-compartment model did not provide a 
better fit to the data. Weight was included in the base CL and V models (Table 3.3). An 
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estimation of the body size exponent (weightθ) was explored as a potential body size model 
for CL and V; however, it was excluded due to lack of improvement in model fit and 
imprecision around the exponent parameter estimate. After incorporating weight in the base 
model, it was not possible to estimate IIV in V. An evaluation of the model prior to the 
addition of weight as a covariate for V demonstrated high shrinkage in V IIV (47%). This 
finding suggested that the V IIV parameter estimate deviated from a normal distribution 
leading to non-parametric estimation of this parameter. However, once weight was 
reincorporated into the model, the V IIV parameter was estimated with a value close to zero 
via non-parametric methods and was excluded during the model-building process. Age- and 
maturity-related covariates (PNA, PMA) as well as SCR showed correlation with 
unexplained CL (ETA1) IIV (Fig. 3.1). During the univariable evaluation (after inclusion of 
body weight), all age-related covariates as well as SCR resulted in a significant decrease in 
the objective function value (OFV) (Table 3.3). The largest drop in OFV occurred when SCR 
was added to the model. However, when the SCR outlier indicator variable was used, the 
change in OFV was not as pronounced as that observed with addition of maturation 
covariates. This suggested that the significant association between SCR and CL was 
influenced by an outlier observation (Table 3.3). In the multivariable analysis, the addition of 
SCR did not improve the model goodness of fit nor did it significantly decrease the OFV 
(Tables 3.3 and 3.4). When the bias of scavenged samples was evaluated in the error model 
of the final population PK model, underestimation of metronidazole concentrations by 30% 





Population PK model evaluation 
 The final model had good precision as evidenced by relative standard errors around 
the parameter point estimates of 11–30% and by 95% confidence intervals generated by 
bootstrapping (N=1000 simulated trials, 997 successful runs) (Table 3.4). Goodness-of-fit 
diagnostic plots for the final model are shown in Fig. 3.2. The visual predictive check 
revealed a good fit between observed and predicted metronidazole concentrations (Fig. 3.3). 
Only 7% (8/116) of observed concentrations were outside of the 90% prediction interval. 
  
Bayesian estimates of CL, V, and half-life 
 The median individual empirical Bayesian estimates for CL, V, and half-life were 
summarized by GA group (Table 3.5). There was a trend towards increasing median 
metronidazole weight-normalized CL and decreasing half-life with increasing GA group. 
Consistent with the PMA covariate influence in the final population PK model, weight-
adjusted metronidazole CL increased with increasing PMA and decreased with increasing 
SCR (Fig. 3.4).  
  
Dose-exposure relationship 
 Over 70% of all infants included in this study achieved the PD target (steady-state 
trough concentrations > than an MIC of 8 mg/L) (Fig. 3.5, Table 3.2). In contrast, <70% of 
subjects across GA groups achieved the target when dosing recommendations by Neofax and 
The Harriet Lane Handbook were used in simulated datasets (Fig. 3.5 and 3.6). The smallest 
proportion of preterm infants who achieved the PD target was observed in the 30–32-weeks 
BGA group and infants with PNA >60 days (Fig. 3.5 and 3.6). In contrast, 90% of subjects 
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regardless of BGA group and PNA achieved the target when the PMA-based dosing scheme 
was used in simulated datasets. Higher steady-state metronidazole trough concentrations 
were predicted by the PMA-based dosing regimen when compared with the other regimens, 
and therapeutic concentrations (median) were achieved after a loading dose on the first day 
of therapy (Fig. 3.5 and 3.7).  
 
Discussion 
Most antimicrobial products used in preterm infants lack PK information specific to 
the unique physiology of prematurity. Without appropriate studies specifically designed for 
preterm infants, clinicians are often forced to prescribe products “off-label,” exposing 
patients to potential adverse drug effects or less-than-optimal drug exposure without dosing 
evidence.14,15 
In the present study, the scavenged sampling technique was used to successfully 
develop a population PK model and new metronidazole dosing recommendations for preterm 
infants. The newly proposed PMA-based dosing regimen compared very favorably against 
published schemes5,6; a higher proportion (~90%) of subjects achieved the therapeutic target 
in simulated datasets. The PMA-based dosing scheme was particularly effective in more 
mature (30–32 weeks) and older (PNA >60 days) infants where suboptimal metronidazole 
concentrations were achieved when published guidelines were used in simulated datasets. To 
achieve higher concentrations in more mature infants, a cutoff of 34 weeks PMA was chosen 
to increase the dosing frequency in the PMA-based dosing regimen. This decision was based 
upon examination of the relationship between weight-adjusted CL and PMA (Fig. 3.4) 
where, at 34 weeks, the rate of change in metronidazole CL increased. A higher proportion of 
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subjects achieved the therapeutic target with the newly proposed regimen, while trough 
concentrations in each BGA group were similar to those observed with current routine 
medical care (Fig. 3.5). These data suggest that safety should not be different between the 
new dosing regimen and current clinical practice, but further prospective studies are 
warranted to verify this finding. 
PMA-based dosing has proven successful in the evaluation of other therapeutics in 
preterm infants. A population PK study of 80 neonates with PMA 25–44 weeks demonstrated 
that PMA-based dosing of amikacin achieved the therapeutic target in over 90% of infants.9 
Similarly, PMA-based dosing was successful in 70 preterm infants (PMA 25–48 weeks) 
receiving vancomycin and 50 preterm infants treated with intravenous acetaminophen.7,8 
Because the present study did not evaluate efficacy or clinical outcomes, a surrogate 
PD endpoint was used for the study population receiving metronidazole per routine clinical 
care and in simulated datasets. In this study, the majority of subjects (>70%) receiving 
metronidazole per routine medical care achieved the surrogate PD target for efficacy. In 
contrast, when dosing recommendations published in commonly used pediatric sources were 
used in simulated datasets, a lower proportion of subjects achieved the surrogate PD target. 
This finding may be due to higher doses (more frequent administration) prescribed per 
routine medical care when compared with published regimens and suggests that prescribing 
practices in the neonatal intensive care unit are not driven by these sources.5,6  
In adults, metronidazole undergoes extensive hepatic metabolism with subsequent 
renal elimination16; the elimination half-life is 8 hours,17 20% is protein-bound, and the 
apparent V ranges between 0.25 and 0.85 L/kg.17 The hepatic metabolizing and renal 
elimination systems undergo ontogenic changes during infancy, resulting in increased CL 
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with increasing size and age.18,19 In young infants, metronidazole PK differs substantially 
from adults; the elimination half-life is 2–3-fold longer, and it decreases with increasing GA 
at birth and PNA.20–23 Not surprisingly, in the present model, metronidazole CL increased 
proportionally with weight and disproportionally with PMA, and both covariates explained a 
substantial amount (~80%) of the CL IIV. This finding is consistent with prior observations 
in a metronidazole population PK study of 32 preterm infants (PMA 25–38 weeks) using 
dried blood spots (DBS) where body weight and PMA explained ~93% of the CL IIV.22 The 
population PK parameter estimates in the present study are also comparable to those 
estimated in the DBS study. The CL estimate in a typical preterm infant with PMA 26 weeks 
in the present study was 0.014 L/h vs. 0.013 L/h in the DBS study. Similarly, CL estimates of 
a typical infant with PMA 32 weeks were 0.050 and 0.048 L/h, respectively. Estimates of 
population V in both studies were identical.22 Other smaller, single-center studies have also 
shown similar associations between metronidazole CL and maturation and metronidazole V 
and weight.20,21  
The addition of SCR into the multivariable CL model did not improve the goodness 
of fit, nor did it significantly explain remaining CL IIV. Due to ontogenic changes in renal 
function among preterm infants, SCR is strongly linked with maturational components such 
as PMA. This observation likely prevented our ability to discern the effect of the 
maturational component in CL IIV from SCR in the CL model-building process. The 
population PK model developed performed well during model evaluation and showed good 
precision around parameter estimates. After incorporation of weight as a covariate for V, the 
IIV estimate on V was close to zero. It is plausible that in the subjects enrolled in this study, 
weight explained all the IIV in V. It is also possible that the data were uninformative to 
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estimate the V IIV due to a very narrow distribution of V IIV resulting from sparse 
sampling.24  
The bias introduced by scavenged sampling was quantified in this study and resulted 
in an underestimation of metronidazole concentrations by ~30%. This finding suggests that 
collecting scavenged samples from the clinical laboratory is a viable strategy to describe 
metronidazole PK and is further supported by the environmental stability of metronidazole 
for up to 48 hours.25 However, during bootstrap procedures, imprecision was observed 
around the scavenged sample fixed parameter estimate (95% CI 10–42%). To more precisely 
estimate the amount of bias introduced by scavenged samples, a higher number of timed 
samples should be obtained. As expected, the residual variability (RV) estimated for 
scavenged samples was higher than that estimated for timed specimens. This finding could be 
due to higher documentation errors associated with sampling or dosing times extracted from 
the medical record after a scavenged sample was collected. In addition, information 
regarding the duration and conditions under which the samples remained in the clinical 
laboratory before freezing were not collected, which could add to the increased RV in 
scavenged samples.  
In summary, the minimal-risk approach of scavenged PK sampling was an effective 
methodology to describe the population PK of metronidazole in preterm infants, to identify 
covariates that explain CL IIV, and to provide dosing recommendations in this population. 
After scaling for size, incorporating PMA as a covariate explaining CL IIV increased the 
model fit and led to a newly proposed, more simplistic dosing regimen based on PMA. 
Future efforts evaluating this methodology should consider the physicochemical properties of 
the drug (i.e., drug stability), more detailed documentation of sample collection and storage 
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conditions, and simultaneous collection of traditional plasma samples to fully assess the 




1. Wade KC, Wu D, Kaufman DA, et al.; National Institute of Child Health and 
Development Pediatric Pharmacology Research Unit Network. Population 
pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 
2008;52(11):4043–4049. 
 
2. Uhari M, Seppänen J, Heikkinen E. Imipenem-cilastatin vs. tobramycin and 
metronidazole for appendicitis-related infections. Pediatr Infect Dis J. 1992;11(6):445–
450. 
 
3. Brook I. Bacteremia due to anaerobic bacteria in newborns. J Perinatol. 1990;10(4):351–
356. 
 
4. Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: pathogenesis, 
prevention and management. Drugs. 2008;68(9):1227–1238. 
 
5. Tschudy M, Arcara K. The Harriet Lane Handbook: A Manual for Pediatric House 
Officers. 19th ed. Philadelphia, PA: Mosby; 2011. 
 
6. Thomson Reuters Clinical Editorial Staff. Neofax 2011. 24th ed. Montvale, NJ: Thomson 
Reuters; 2011. 
 
7. Marqués-Miñana MR, Saadeddin A, Peris JE. Population pharmacokinetic analysis of 
vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin 
Pharmacol. 2010;70(5):713–720. 
 
8. Palmer GM, Atkins M, Anderson BJ, et al. IV acetaminophen pharmacokinetics in 
neonates after multiple doses. Br J Anaesth. 2008;101(4):523–530. 
 
9. Sherwin CM, Svahn S, Van der Linden A, et al. Individualised dosing of amikacin in 
neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol. 
2009;65(7):705–713. 
10. Smith PB, Cohen-Wolkowiez M, Castro LM, et al.; Meropenem Study Team. Population 
pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with 
suspected or complicated intra-abdominal infections. Pediatr Infect Dis J. 
2011;30(10):844–849. 
 
11. Cohen-Wolkowiez M, White NR, Bridges A, Benjamin DK Jr, Kashuba AD. 
Development of a liquid chromatography-tandem mass spectrometry assay of six 
antimicrobials in plasma for pharmacokinetic studies in premature infants. J Chromatogr 




12. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and 
pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 
1999;36(5):353–373. 
 
13. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility 
Testing of Anaerobic Bacteria; Approved Standard. 7th ed. CLSI document M11-A7. 
Wayne, PA: CLSI; 2007. 
 
14. Choonara I. Unlicensed and off-label drug use in children: implications for safety. Expert 
Opin Drug Saf. 2004;3(2):81–83. 
15. Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling: improving the 
safety and efficacy of pediatric therapies. JAMA. 2003;290(7):905–911. 
 
16. Schwartz DE, Jeunet F. Comparative pharmacokinetic studies of ornidazole and 
metronidazole in man. Chemotherapy. 1976;22(1):19–29. 
 
17. Houghton GW, Smith J, Thorne PS, Templeton R. The pharmacokinetics of oral and 
intravenous metronidazole in man. J Antimicrob Chemother. 1979;5(5):621–623. 
 
18. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental 
pharmacokinetics of morphine and its metabolites in neonates, infants and young 
children. Br J Anaesth. 2004;92(2):208–217. 
 
19. de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. 
Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin 
Pharmacol. 2002;53(4):390–392. 
 
20. Hall P, Kaye CM, McIntosh N, Steele J. Intravenous metronidazole in the newborn. Arch 
Dis Child. 1983;58(7):529–531. 
 
21. Jager-Roman E, Doyle PE, Baird-Lambert J, Cvejic M, Buchanan N. Pharmacokinetics 
and tissue distribution of metronidazole in the new born infant. J Pediatr. 
1982;100(4):651–654. 
 
22. Suyagh M, Collier PS, Millership JS, et al. Metronidazole population pharmacokinetics 
in preterm neonates using dried blood-spot sampling. Pediatrics. 2011;127(2):e367–374. 
 
23. Upadhyaya P, Bhatnagar V, Basu N. Pharmacokinetics of intravenous metronidazole in 
neonates. J Pediatr Surg. 1988;23(3):263–265. 
81 
 
24. Baverel PG, Savic RM, Wilkins JJ, Karlsson MO. Evaluation of the nonparametric 
estimation method in NONMEM VI: application to real data. J Pharmacokinet 
Pharmacodyn. 2009;36(4):297–315. 
 
25. Menelaou A, Somogyi AA, Barclay ML, Bochner F. Simultaneous quantification of 
amoxycillin and metronidazole in plasma using high-performance liquid chromatography 
with photodiode array detection. J Chromatogr B Biomed Sci Appl. 1999;731(2):261–
266.   
82 
 
Table 3.1. Dosing schemes used to assess pharmacodynamic target achievement 
BW 





kg weeks days weeks mg/kg mg/kg hours 
The Harriet Lane Handbook  
<1.2 NA ≥7 NA NA 7.5 24 
1.2–2 NA ≥7 NA NA 7.5 12 
≥2 NA ≥7 NA NA 15 12 
Neofax  
NA NA ≤28 ≤29 15 7.5 48 
NA NA >28 ≤29 15 7.5 24 
NA NA ≤14 30–36 15 7.5 24 
NA NA >14 30–36 15 7.5 12 
NA NA ≤7 37–44 15 7.5 24 
NA NA >7 37–44 15 7.5 12 
NA NA ALL ≥45 15 7.5 6 
PMA-based dosing regimen 
NA ≤32 NA <34 15 7.5 12 
NA ≤32 NA 34–40 15 7.5 8 
NA ≤32 NA >40 15 7.5 6 
 
BW: birth weight; GA: gestational age; PMA: postmenstrual age; PNA: postnatal age. 
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Table 3.2. Clinical data by gestational age group 
  Gestational age at birth 
Characteristic <26 weeks 26–29 weeks 30–32 weeks 
N 13 14 5 
Gestational age, weeks 24 (22, 25) 28 (26, 29) 31 (30, 32) 
Postnatal age, days 29 (2, 71) 32 (2, 78) 29 (10, 73) 
Postmenstrual age, 
weeks 32 (24, 39) 32 (28, 43) 36 (32, 40) 
Weight, g 1410 (678, 2537) 1510 (850, 3611) 1658 (1230, 3850) 
Female sex 6 (46) 9 (64) 2 (40) 
White race 4 (31) 10 (71) 2 (40) 
Hispanic 1 (8) 2 (14) 0 (0) 
Serum creatinine 
(mg/dL) 0.5 (0.3, 4.7) 0.5 (0.2, 1.2) 0.2 (0.1, 0.6) 
Dose (mg/kg) 7.6 (4.2, 14.2) 7.8 (6.2, 15.1) 9.0 (6.5, 15.4) 
Dosing frequency (h) 11.9 (5.9, 48.2) 12 (5.9, 48) 12.3 (11.2, 26.7) 
 









Table 3.3. Model-building process 
Base model and 
univariable 
analysis Population model OFV ΔOFV 
V V = θV X (wt/1.5) 498 - 
CL base model CL = θCL X (wt/1.5) 498 - 
PMA CL = θCL X (wt/1.5) X (PMA/32)θCL-PMA 484.5 -13.5 
PNA CL = θCL X (wt/1.5) X (PNA/57)θCL-PNA 486.4 -11.6 
SCR CL = θCL X (wt/1.5) X (0.5/SCR)θCL-SCR 483.7 -14.3 
SCR + indicator CL = θCL X (wt/1.5) X (0.5/SCR)θCL-SCR X CR 487.2 -10.8 
Multivariable 
model       
CL, PMA, and 
SCR CL = θCL X (wt/1.5) X (PMA/32)θCL-PMA X (0.5/SCR)θCL-SCR 480.8 -3.7 
 
CL: clearance; OFV: objective function value; PMA: postmenstrual age; PNA: postnatal age; 
















2.5% Median 97.5% 
CL (L/h) θCL 0.0397 10.9 0.0307 0.0398 0.0483 
V (L) θv 1.07 15.0 0.85 1.12 1.37 
CL, PMA θCL-PMA 2.49 29.8 1.01 2.57 4.20 
SCAV θSCAV 0.713 12.3 0.581 0.721 0.899 
Inter-individual variance             
CL (CV%) ω2CL  42.5 28.5 24.2 40.4 52.8 
Residual variance (CV%)             
Blood draws σ12 13.5 24.5 0.3 13.3 15.7 
Scavenged σ12 29.0 17.9 23.7 27.8 34.9 
 
CI: confidence interval; CL: clearance; CV: coefficient of variation; PMA: postmenstrual 














Fig. 3.1. Base model scatter plots of CL ETA1 estimates and the following: BGA (A), PNA 






Fig. 3.2. Final population PK model diagnostic plots: observed vs. population predictions (A) 
and individual predictions (B); weighted residuals vs. population predictions (C) and time 
(D). For A and B, the line of identity is included as a reference. For weighted residuals, a 






Fig. 3.3. Visual predictive check of metronidazole concentrations versus time. Solid black 
circles represent observed concentrations. Shaded gray area represents the 90% prediction 







Fig. 3.4. Weight-normalized metronidazole clearance versus postmenstrual age (A) and 







Fig. 3.5. PD target attainment rates by gestational age group: proportion of study subjects 
who met PD target with dosing prescribed per routine medical care (A); predicted steady-
state metronidazole trough concentrations in study subjects (B); proportion of simulated 
subjects who met PD target with different dosing schemes (C); and predicted steady-state 
metronidazole trough concentrations in simulated subjects (D). Red line represents 80% 














Fig. 3.6. PD target attainment rates by gestational age group and postnatal age in simulated 
subjects: GA group <26 weeks (A); GA group 26–29 weeks (B); GA group 30–32 weeks 












Fig. 3.7. Simulated time-concentration profiles with proposed PMA dosing regimen in 
typical subjects: PMA 26 weeks, weight 900 g (A); PMA 32 weeks, weight 1900 g (B); PMA 
36 weeks, weight 2800 g (C); PMA 41 weeks, weight 3800 g (D). Shaded gray area 
represents the 90% prediction interval around the loading dose simulations. Solid and dashed 













CHAPTER 4: PIPERACILLIN AND TAZOBACTAM IN DRIED BLOOD SPOTS: 
ASSAY DEVELOPMENT AND CLINICAL APPLICATION IN PRETERM INFANTS 
 
Introduction 
 Pharmacokinetic (PK) studies in preterm infants are exceptionally scarce due to the 
challenges associated with traditional clinical trial design in this vulnerable population. These 
challenges include low rates of informed consent among parents of critically ill infants; lack 
of availability of sensitive drug concentration assays; and limited blood volume necessary to 
conduct PK studies. These limitations have forced investigators to rely on the extrapolation 
of PK data obtained in older children and adults to estimate PK parameters and provide 
dosing recommendations in preterm infants. However, this approach underestimates the 
complicated physiology of preterm infants, which differs greatly from other populations. 
Preterm infants have a larger extracellular fluid volume, immature renal and hepatic function, 
underdevelopment of metabolic enzymatic systems, and a unique blood-brain barrier—all of 
which can substantially alter drug disposition.1 
 Dried blood spot (DBS) sampling is an established technology used globally in 
neonatal screening. The DBS sampling method involves the collection of 15–30 uL of whole 
blood on blotting paper. Given the small blood volumes required for DBS sampling, this 
technology has emerged as an attractive tool in pre-clinical and clinical PK studies.2,3 In 
addition, DBS sampling appeals to the pediatric research community as a potential tool for 
overcoming blood volume limitations in this population. However, the use of DBS in 
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pediatric clinical trials is extremely scarce; only 1 study using DBS technology in preterm 
infants has been published.3 This could be the result of a lag time in adopting emerging 
technologies, as well as a lack of DBS assay development for drugs commonly used in 
children. The present study describes the development of a liquid chromatography-tandem 
mass spectrometry (LC−MS/MS) assay of piperacillin and tazobactam in DBS and its 
application to clinical samples collected from preterm infants.  
 
Methods 
Chemicals and reagents 
 Piperacillin and dicloxacillin (internal standard [IS]) were purchased from the Sigma 
Chemical Company (St. Louis, MO, USA). Tazobactam was purchased from the U.S. 
Pharmacopeia (Rockville, MD, USA). High-performance liquid chromatography (HPLC)-
grade chemicals were purchased from Fisher Scientific (Norcross, GA, USA). Purified 
compressed nitrogen was obtained from Airgas-National Welders (Charlotte, NC, USA). 
Drug-free pooled whole blood was obtained from Biological Specialty Corporation (Colmar, 
PA, USA). Whole blood was anticoagulated with potassium tri-phosphate 
ethylenediaminetetraacetic acid (EDTA).  
 
Equipment 
 Compounds were analyzed with a triple quadrupole mass spectrometer API 4000 
(Applied Biosystems–ABSciex, Foster City, CA, USA). A Shimadzu solvent delivery system 
(Columbia, MD, USA), LEAP HTC PAL thermostatted autosampler (Carrboro, NC, USA), 
Valco switching valve (Houston, TX, USA), and Analyst Software version 1.4.1 (Applied 
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Biosystems–ABSciex, Foster City, CA, USA) run on a Dell desktop computer (operated by 
Windows XP professional) were used for this method. DMPK FTA Type-C cards (Whatman, 
GE Healthcare, Kent, UK) and Harris Uni-Core 6.0 MM punchers were purchased from 
Fisher Scientific (Norcross, GA, USA).  
 
Preparation of standards 
 Individual clear stock solutions of piperacillin and tazobactam were prepared at a 
concentration of 15 mg/mL. Each analyte was accurately weighed and dissolved in 1 mL of 
dimethyl sulfoxide (DMSO). The master stock solution was prepared as a composite of the 2 
compounds (0.5 mL each), adjusted to a final concentration of 1,500,000 ng/mL for each 
analyte by 4.0 mL of DMSO. This master stock standard was used to prepare 7 intermediate 
composite stock solutions: piperacillin (1,500,000, 750,000, 300,000, 150,000, 30,000, 
15,000, and 3,000 ng/mL) and tazobactam (750,000, 300,000, 150,000, 30,000, 15,000, 
3,000, and 1,500 ng/mL). 
 Whole blood working calibration solutions at 150,000, 75,000, 30,000, 15,000, 3,000, 
1,500, and 300 ng/mL for piperacillin and 75,000, 30,000, 15,000, 3,000, 1,500, 300, and 150 
ng/mL for tazobactam were prepared by diluting the intermediate solutions in human drug-
free fresh whole blood in a ratio of 1:9. Twenty-five microliters of each working calibration 
solution were spotted onto DMPK FTA Type-C cards and left to dry for 4 hours. From the 
master and intermediate stock solutions, quality control (QC) intermediate stock solutions 
were prepared in DMSO at concentrations of 9,000, 600,000, and 1,200,000 ng/mL for 
piperacillin and 4,500, 180,000, and 600,000 ng/mL for tazobactam. Whole blood working 
QC samples of 900, 60,000, and 120,000 ng/mL for piperacillin and 450, 18,000, and 60,000 
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ng/mL for tazobactam were prepared by diluting the QC intermediate solutions in human 
drug-free fresh whole blood in a ratio of 1:9. Twenty-five microliters of each working QC 
solution were spotted onto DMPK FTA Type-C cards and left to dry for 4 hours. 
 
Internal standard preparation 
 Dicloxacillin (1 mg) was weighed and dissolved in DMSO to achieve a final 
concentration of 1.0 mg/mL (stock solution). The IS working solution was prepared by 
diluting 0.3 mL of this solution in 75% methanol:water to achieve a final concentration of 
3,000 ng/mL. 
 
Samples and pre-treatment 
 This method was used to measure antimicrobial concentrations in clinical samples 
collected from preterm infants. Sample collection (~1 drop onto card) occurred under an 
investigational protocol approved by the institutional review board at participating sites and 
after informed consent was obtained from caregivers of study participants. Samples were 
obtained at the same time as plasma samples and could be obtained after single or multiple 
dosing. DBS samples were left out to dry for up to 4 hours, were placed in a zip-lock bag 
including a desiccant and humidity indicator, and then were transferred to a −80° C 
temperature-monitored freezer for storage until analysis. DBS samples were collected from 
intravascular devices, venipunctures, arterial sites, or capillary heel sticks. Prior to extraction, 
all DBS cards were brought to room temperature for 2 hours and all cards were photographed 
using a digital camera. DBS samples were compared with paired plasma samples that were 
previously analyzed with a validated method.4 Two independent observers classified each 
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DBS sample into 2 categories, valid and non-valid. Criteria for a non-valid samples included 
appearance of multiple drops of blood per each spot on the card, asymmetry of spot, and 
cross-contamination between spots on the same card. The ratio of DBS/plasma concentration 
ratio was calculated for each sample for both compounds. The correlation between DBS and 
plasma concentrations was assessed with scatter plots and weighted (variance of y) linear 
regression. Hematocrit (Hct) values were recorded for each participant if collected during 
routine medical care. Hct values obtained prior to sample collection were carried forward if 
the value was missing at the time of DBS sample collection.  
 
The extraction procedure 
 On the day of analysis, 6 mm out of the center of 1 spot from each DBS card was 
punched into a 2.0 mL labeled conical plastic Eppendorf tube. Two hundred microliters of 
internal standard in 75% methanol:water was added into the Eppendorf tube containing the 
punched DBS sample. The solutions were gently vortex-mixed for 10 minutes and 
centrifuged at 15,600 g at 4o C for 5 minutes. The supernatant portion was transferred into a 
96-insert holder with 0.7 mL glass inserts (Q Glass, Towaco, NJ, USA). The inserts on the 
holder were tightly sealed with a silicone 96-insert cover. 
 
LC-MS/MS analysis 
 Piperacillin was analyzed in positive mode and tazobactam was analyzed in negative 
mode during a separate injection run from the same glass insert. Dicloxicillin was used as 
internal standard for both positive and negative analyses. The injection volume was 4 µL. 
Chromatography was achieved by using a reverse-phase C18 Aquasil column (50 x 2.1-mm 
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internal diameter, 5 μm particle size; Thermo Fisher, Waltham, MA, USA) with a flow rate 
of 0.75 ml/min for analysis in positive mode and a C18 Ultra Aqueous column (50 x 2.1-mm 
internal diameter, 3 μm particle size; Restek, Bellefonte, PA, USA) with a flow rate of 0.35 
ml/min for analysis in negative mode. In both analyses, mobile phase A consisted of 0.1% 
formic acid in water, and mobile phase B consisted of 0.1% formic acid in methanol. The 
chromatographic separation of analytes was performed with gradient elution of increasing 
mobile phase B (0% hold until 0.7 minutes, 0–15% from 0.7–1 minute, 15–100% from 1–4 
minutes, 100% hold from 4–4.5 minutes, 0% from 4.5–6 minutes for positive mode; 0% hold 
until 0.7 minutes, 0–100% from 0.7–2.5 minutes, 100% hold from 2.5–3.5 minutes, 0% from 
3.5–5 minutes for negative mode). Flow was diverted to waste for the first 0.7 minutes and 
after 4 minutes. Total run time was 6 and 5 minutes for positive and negative mode, 
respectively. 
 MS/MS analysis was performed on a triple quadrupole mass spectrometer API 4000 
(Applied Biosystems–ABSciex, Foster City, CA, USA) operated with electrospray ionization 
(TurboV source using the electrospray probe). Ionspray voltage and turbo heater temperature 
were kept at 2500 V (-2000 V for tazobactam) and 500o C, respectively. Compound-specific 
instrument parameters were optimized for each transition (Table 4.1) to obtain the most 
robust signal. 
 
Linearity, limit of quantification, and limit of detection 
 Linearity was assessed using 5 calibration curves analyzed on 3 separate days. For 
validation, each point on the calibration curve was run in duplicate (2 separate extractions), 
and the curves were constructed by calculating the peak area ratios of each compound to the 
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internal standard and plotting these against the nominal concentration of the sample. Back-
calculated calibration concentrations were determined using several models. The calibration 
curve with the best accuracy and precision throughout the curve range was considered the 
best fit. Quadratic regression of the ratio of compound to IS concentration (x) versus peak 
area ratio of compound to IS (y) using a 1/(x) weighting scheme was used for calculations 
because it provided the best fit to the data.  
 The upper limit of quantification (ULOQ) was defined as the highest standard 
concentration for which both the relative standard deviation and the percent deviation from 
the nominal concentration were less than 15%.6 The lower limit of quantification (LLOQ) 
was defined as the lowest concentration for which both the relative standard deviation and 
the percent deviation from the nominal concentration were less than 20%.  
Accuracy, precision, and recovery 
 Accuracy and precision of the analytical method was quantified using 4 
concentrations of QC samples (including LLOQ) run 6 times (6 separate extractions) in 
sequence on 3 different days (total of 18 replicates for each concentration). In addition, 
accuracy and precision of diluted samples were determined. Dilutions (1:1, 1:3, and 1:9 
ratios) of a highly concentrated piperacillin solution (300,000 ng/mL) were performed after 
the extraction process with extract from blank DBS samples. The calculated concentrations 
were compared to the nominal concentrations. Recovery was calculated from peak area 
responses of 2 solutions (A and B). Solution A was the extract of a 25 µL DBS QC extracted 
using the extraction solvent (75% methanol:water). Solution B contained the extract of 25 µL 
blank DBS extracted using the extraction solvent (75% methanol:water) containing 
piperacillin and tazobactam at concentrations equal to the nominal QC values. Recovery (%) 
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was determined as A/B*100, and the following QC concentration levels were used: 12,500 
ng/mL, 25,000 ng/mL, and 50,000 ng/mL. The whole blood spot (rather than a 6 mm punch) 
was used to estimate recovery. 
 
Stability 
 To test stability of analytes during the DBS card drying process, samples were left at 
room temperature for up 4 hours prior to extraction. DBS samples were extracted in 
duplicates at the following time points: 15, 30, 120, and 240 minutes. Mean peak areas of 




 The calibration curve was calculated using peak area ratio values at 7 standard 
concentrations. A quadratic regression provided the best fit to the data. The data for the 
calibration curves (n=3) are shown in Table 4.2, along with the mean ± standard deviation of 
3 standard curve quadratic coefficients, slopes, intercepts, and correlation coefficients (r2). 
The regression coefficient (r2) for all calibration curves was greater than 0.9965.  
 
The limit of quantification 
 The LLOQ for piperacillin was 300 ng/mL and for tazobactam 150 ng/mL, and the 
ULOQ for piperacillin was 150,000 ng/mL and for tazobactam 75,000 ng/mL. 
Chromatograms of blank, LLOQ, and ULOQ samples are shown in Fig. 4.1 and Fig. 4.2. 
Accuracy, precision, and recovery 
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 The results of the accuracy and precision experiments at 4 different QC levels for 
piperacillin and 3 QC levels for tazobactam are shown in Table 4.3. Within-day accuracy of 
both analytes ranged from 96–112%, with a mean of 103%. Between-day accuracy of both 
analytes ranged from 96–110%, with a mean of 103%. Within- and between-day coefficient 
of variations varied from 4.3–9.7% and 5.4–10.3%, respectively. Overall, results indicate that 
the method was accurate and precise for both compounds. In addition, piperacillin 
concentration measurements of partially diluted samples were accurate and precise across all 
dilution ratios (Table 4.4). The greatest percent deviation for all diluted samples was 11.5% 
when diluted 1:9. The greatest percent coefficient of variation for all diluted samples was 
5.6%. The absolute recovery of all compounds at all concentrations was greater than 79% for 
piperacillin and 65% for tazobactam (Table 4.2). 
 
Stability 
 Peak area changes were not observed during the DBS card drying process for 
piperacillin and tazobactam (Fig. 4.3). Piperacillin and tazobactam response (peak area) was 
slightly lower (<15%) at 15 minutes when compared with later time points.  
 
Analysis of patient samples 
 The applicability of the described method was evaluated by analyzing DBS samples 
(N=56 total, 47 with paired plasma) collected from premature infants given multiple 
intravenous doses of piperacillin-tazobactam. Ten samples were identified as non-valid due 
to the presence of multiple drops of blood per each spot on the card and cross-contamination 
between cards; 37 sample pairs were included in the analysis. The median (5, 95%) 
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piperacillin concentrations in plasma and DBS were 107.0 (15.4, 249.0) mg/L and 49 (11.9, 
103) mg/L, respectively; and for tazobactam 12.2 (1.94, 26.4) mg/L and 5.8 (1.02, 13.3) 
mg/L, respectively. The DBS-to-plasma concentration ratio for piperacillin and tazobactam 
can be seen in Table 4.5. The overall median ratio of piperacillin DBS-to-plasma ratio was 
0.37 (range, 0.20, 3.01) and for tazobactam was 0.50 (0.21, 1.41). A strong association was 
observed between DBS and plasma concentrations for both piperacillin and tazobactam (r2= 
0.81 and 0.80, respectively; p<0.001) (Fig. 4.4). No trends were observed between the 
piperacillin and tazobactam DBS-to-plasma ratios and the range of plasma concentrations 
(Fig. 4.4).  
 
Discussion  
 The method described successfully measures drug concentration of piperacillin and 
tazobactam in DBS samples. Other investigators have successfully measured antimicrobials 
in DBS, including antiretroviral, antimalarial, and anti-tuberculous drugs7–9; however, this is 
the first report of DBS sample analysis of a beta-lactam antibiotic. The ability to measure 
drug concentrations of antimicrobials in DBS samples is an important milestone in evaluating 
drug disposition in preterm infants This method involves a very simple extraction process 
and a short run time ideal for high throughput application. In addition, DBS clinical samples 
required an 8-fold lower blood volume than traditional PK plasma samples, virtually no 
sample processing, and convenient storage. The combination of these factors makes DBS 
sampling an ideal matrix for PK analysis in preterm infants. Also, piperacillin and 
tazobactam demonstrated on-card stability throughout the drying process. Peak area for both 
analytes was slightly lower at 15 minutes when compared with later time points, which could 
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have resulted from incompletely dried sample at 15 minutes and potential analyte hydrolysis. 
In addition to the benefits described above, the comparison of DBS (whole blood) drug 
concentrations to plasma of preterm infants provides new insights into the red blood cell 
partition of drugs in this population. Partition of drugs into red blood cells is usually 
evaluated during drug development using in vitro techniques under controlled conditions or 
in healthy volunteers.10 However, extrapolation of these findings to in vivo physiology is 
controversial because red blood cell partition is dependent on blood pH, temperature, and 
protein binding, which can behave differently in vivo. An example of this discrepancy was 
evident during the evaluation of phenobarbital red blood cell partitioning in neonates and 
their mothers. In neonates, phenobarbital partitioning was lower relative to their mothers.11 
Because phenobarbital binds to hemoglobin, this finding suggested a different affinity of 
phenobarbital to fetal hemoglobin present at birth.  
 Piperacillin and tazobactam concentrations in DBS samples were strongly associated 
with measurements in plasma samples; overall, DBS piperacillin and tazobactam 
concentrations were lower than plasma. This was evidenced by median DBS-to-plasma 
concentration ratios of 0.37 and 0.50 for piperacillin and tazobactam, respectively. This 
difference is not unexpected given the assumption that piperacillin and tazobactam do not 
partition into red blood cells.12 In this setting, the red blood cells in DBS samples act as a 
diluent resulting in lower DBS drug concentrations. Consequently, the difference between 
the DBS-to-plasma ratio and unity should approach the hematocrit value, as was evident for 
both drugs. In some cases, however, the DBS-to-plasma ratio for piperacillin was lower than 
expected even after consideration of hematocrit. This was more evident at higher (>150 
mg/L) piperacillin plasma concentrations. It is plausible that piperacillin degraded at room 
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temperature13 during the DBS sample drying process. However, unless clinical samples were 
left to dry for periods longer than 4 hours, drug degradation is unlikely given our stability 
results during a 4-hour period. It is also possible that DBS measurements had measurement 
errors related to inconsistency in sample collection techniques across sites and use of 
multiple blood sources (i.e., with and without anticoagulant) before spotting on the card. The 
presence of EDTA in clinical samples has been shown to produce ion enhancement of certain 
compounds.14 Inconsistency in sample collection technique could also account for the degree 
of variability seen in DBS-to-plasma concentration ratios for both drugs. Even though the 
DBS-to-plasma ratio for both drugs suggested little to no partitioning into red blood cells, 
there are no published reports addressing this question. Future studies are required to confirm 
these findings. 
 We successfully developed a method to simultaneously assay piperacillin and 
tazobactam in DBS samples. The assay was validated with respect to accuracy, precision, 
limit of detection, recovery, and stability, and has been successfully applied to clinical 
samples from preterm infants. This method has many clinical applications within the field of 
pediatrics, as it is simple, highly sensitive and specific, and requires ultra-low volumes of 
clinical samples. DBS and plasma piperacillin and tazobactam concentrations were highly 
correlated and on average, piperacillin and tazobactam DBS concentrations were lower than 
plasma. This difference suggests that piperacillin and tazobactam do not partition into red 
blood cells. These data suggest that DBS samples can be used as a surrogate for piperacillin 
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Piperacillin 517.55 Positive 518.2 143.2 10 25 
Tazobactam 300.29 Negative 299.0 137.9 10 -20 
Dicloxacillin 
(IS) 470.32 Positive 470.1 160.1  10  
20 
Dicloxacillin 
(IS) 470.32 Negative 468.0 326.8 10 
-20 
 

























Piperacillin 300 111.83 6.46 109.50 7.32 
  900 96.32 7.08 96.41 7.67 
  60,000 103.35 4.70 101.85 6.05 
  120,000 102.59 4.31 101.30 6.61 
Mean  103.52 5.63 102.27 6.91 
Tazobactam 150 107.63 8.58 105.30 10.33 
  450 97.89 9.65 103.58 8.67 
  60,000 100.55 4.45 101.96 5.43 
Mean   102.02 7.56 103.61 8.14 
 
CV: coefficient of variation.
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Table 4.4. Validation of piperacillin partial dilutions 
 
  Conc. Conc. Conc. 
Piperacillin Dilution 1:1 1:3 1:9 
    
  
Sample # 1 161000 87600 29800 
 
2 159000 78500 31800 
 
3 156000 84800 32600 
    
  
 
Theoretical conc. 150000 75000 30000 
 
mean 158667 83633 31400 
 
SD 2516.6 4660.8 1442.2 
 
% CV 1.6 5.6 4.6 
 
% Dev 5.8 11.5 4.7 
 
n 3 3 3 
 





Table 4.5. DBS and plasma concentrations for piperacillin and tazobactam 
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Data are median (range). 





Fig. 4.1. Blank plasma sample run in a) negative (tazobactam top; dicloxacillin [IS] bottom) 












Fig. 4.2. Lower limit of quantification in a) negative (top to bottom: tazobactam and 
dicloxacillin [IS]) and b) positive (top to bottom: dicloxacillin [IS], piperacillin) ionization 
mode. Upper limit of quantification in c) negative (top to bottom: tazobactam and 
dicloxacillin [IS]) and d) positive (top to bottom: dicloxacillin [IS], piperacillin) ionization 


































Fig. 4.4. Scatter plots of DBS vs. plasma concentrations for a) piperacillin and b) tazobactam. 
Scatter plots of DBS-to-plasma concentration ratio vs. plasma concentrations for c) 
piperacillin and d) tazobactam. DBS: dried blood spot; m: slope. Non-valid samples (N=11) 
are excluded from all panels. One outlier was excluded from panel C (DBS-to-plasma ratio = 












SUMMARY AND FUTURE DIRECTIONS 
 
 The studies included in this proposal evaluated the use of several novel, minimal-risk 
methods to assess the pharmacokinetics (PK) of antimicrobial agents in preterm infants. Such 
minimal-risk methods seek to address the challenges associated with traditional PK study 
designs in preterm infants, which have led to profound knowledge gaps about the 
antimicrobials used most commonly in this vulnerable population. Although the use of 
minimal-risk methods is an attractive strategy for evaluating the PK of drugs in this context, 
they have not been systematically validated across antimicrobial classes, and few studies 
have actually implemented these methods with success.1,2 The utility of minimal-risk 
methods may be drug-dependent as they rely on physicochemical properties of the drug. 
Therefore, the primary goal of this proposal was to evaluate minimal-risk methods using 2 
commonly used antimicrobials with different physicochemical properties. The following 
methods were assessed: the use of scavenged plasma samples to determine the PK of 
piperacillin and metronidazole; the development of a multiplex assay using ultra-low blood 
volumes; and the utility of dried blood spot (DBS) sampling. 
 Scavenged sampling was a successful minimal-risk approach for the development of 
population PK models, as well as for covariate screening for both piperacillin and 
metronidazole. A 1-compartment model appropriately described the PK of both drugs and is 
consistent with prior findings in older children and adults.1,3–7 In addition, serum creatinine 
and postmenstrual age were identified as significant covariates explaining the inter-individual 
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variability in piperacillin and metronidazole clearance, respectively. These findings are also 
consistent with prior reports and suggest that those covariates could be used to design or 
refine existing dosing regimens for this population. Collectively, these are important findings 
because scavenging allowed for development of PK models and covariate relationships using 
samples that otherwise would have been discarded. 
 The use of scavenged sampling could have broad applications in preterm infant drug 
development. Given the low hurdles associated with this sample collection method and the 
high yield of meaningful PK relationships, this strategy should be strongly considered for 
initial PK model development of drugs in preterm infants prior to design and implementation 
of traditional PK studies. As demonstrated for piperacillin and metronidazole, applying 
scavenged sampling can lead to identification of appropriate structural PK models and 
critical PK sampling times, as well as key covariates that could be further refined in follow-
up traditional PK studies. This strategy will eliminate the “blinded” approach in which 
traditional PK trials are designed without any prior PK information. Obtaining scavenged 
sampling PK information prior to conducting traditional PK studies will also lead to a higher 
probability of trial success as it would allow for a more informed and targeted data 
collection. 
 Scavenging of PK samples also proved successful in estimating the bias in 
metronidazole drug concentrations introduced by this methodology relative to scheduled 
blood draws. On average, metronidazole concentrations in scavenged samples were 30% 
lower than those in scheduled blood draws. In addition, residual variability in scavenged 
samples was higher than that associated with blood draws. The latter finding is expected 
given errors associated with retrospective data collection of dosing and sampling times of 
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scavenged samples that contribute to increased variability. Bias introduced by piperacillin 
scavenged samples was not assessed due to the lack of scheduled blood draws for 
comparison. 
 The scavenging approach could also be used to provide definitive dosing 
recommendations for preterm infants; however, based on the piperacillin and metronidazole 
experiences, this application is dependent on the drug being studied and the quality of the 
data collected. During the PK analysis of piperacillin, an important amount of information 
(from about 20 subjects) could not be used in the analysis due to uncertain documentation of 
dosing and sampling times, potential sample contamination, or samples collected during drug 
infusion or intravascular line flush. In addition, after exclusion of these data, PK and 
variability parameter estimates were unexpected and not consistent with the limited 
piperacillin PK information in preterm infants. Estimates of clearance and volume of 
distribution were several-fold higher when compared with published reports.5,6 These 
estimates were also physiologically unreliable. It is plausible that piperacillin degradation in 
scavenged samples was the primary factor influencing the biased PK point estimates. The 
temperature instability of piperacillin is limited to <4–6 hours,8 and scavenged samples could 
have remained at room temperature or in the refrigerator for 48–72 hours prior to freezing. 
As mentioned, lack of scheduled piperacillin blood draws limited the ability to 
counterbalance the bias introduced by scavenged samples in the piperacillin analysis. 
 In contrast, even though most (90%) metronidazole PK samples were scavenged, PK 
and variability point estimates were consistent and physiologically meaningful. This is likely 
due to the excellent temperature stability of metronidazole (unlike that of piperacillin).9 
Therefore, scavenged samples not only provided information regarding the structure of the 
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PK model and influencing covariates, but it also allowed for development of metronidazole 
dosing recommendations for preterm infants. Moreover, it facilitated the development of a 
new, simplified scheme based on postmenstrual age that compared very favorably with 
current dosing guidelines. For this drug, the scavenged sampling approach was a more 
powerful tool to advance drug development in preterm infants. 
 The piperacillin and metronidazole experiences using scavenged samples uncovered 
some advantages and disadvantages of this minimal-risk approach. Advantages included 
enrollment of infants across a wide range of gestational ages to appropriately explore 
covariate associations with PK parameters; collection of about 3 samples per subject; 
minimal demographic data collection to increase study feasibility; collection of clinical data 
of special interest (i.e., serum creatinine) targeted towards the drugs of interest; and 
collection of scheduled blood draws in addition to scavenged samples. Some of the 
limitations of scavenged sampling included uncertainty around dosing and sampling 
collection dates and times; no documentation of time when samples were frozen; no 
documentation of concomitant medication; and limited collection of scheduled blood draws. 
If these limitations are addressed in future trials, scavenged sampling could provide more 
robust data and widen its application across drugs in preterm infants and older children.  
 Another minimal-risk method explored in this dissertation was the measurement of 
piperacillin and tazobactam concentrations in DBS. This sampling technology is of great 
interest for pediatric pharmacologists given that only 15–30 uL of blood is required for PK 
sampling. DBS is also advantageous because of the simplicity of sample processing and 
analysis; however, the application of DBS sampling in infants is limited to 1 clinical trial.1 A 
piperacillin and tazobactam multiplex DBS assay involving simple sample preparation was 
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developed and validated. Piperacillin and tazobactam DBS correlated with paired plasma 
concentrations; on average, piperacillin and tazobactam DBS concentrations were 50–60% 
lower than plasma. This finding suggests that piperacillin and tazobactam do not partition 
into red blood cells, which act as a diluent when DBS (whole blood) concentrations are 
measured. This should be considered when DBS samples are used as a surrogate for plasma 
during PK evaluations of piperacillin and tazobactam. This exploratory DBS analysis 
suggests that DBS can be used to evaluate the PK of piperacillin and tazobactam, but further 
studies are required. 
 The minimal-risk methods evaluated in this proposal proved successful in many 
aspects related to drug development in preterm infants. In the future, prospective trials will 
need to be conducted to validate these findings. A PK study of piperacillin-tazobactam in 
preterm infants has been completed. In this study, 32 preterm infants were enrolled and given 
piperacillin-tazobactam per routine medical care. Scheduled PK blood draws were 
supplemented with scavenged and DBS samples to validate the bias introduced by these 
sampling strategies. Data analysis for this trial is ongoing. Similarly, another study of 24 
preterm infants will validate the use of scavenged and DBS sampling in subjects treated with 
metronidazole. These sampling techniques will also supplement scheduled blood draws. In 
addition to the clinical data of special interest specifically designed for each drug, data 
regarding time of scavenged sample freezing will also be obtained in these trials. With this 
information, it will be possible to establish a time cut-off for utilization of scavenged samples 




 In the future, the Pediatric Trials Network will oversee a clinical trial derived from 
the scavenged sampling experience. The NIH-sponsored Pediatric Opportunistic PK Study 
(POPS) will be conducted in 15 sites across the United States. PK samples will be obtained 
from subjects receiving drugs per routine medical care. The study will include children <21 
years of age and will address an array of drugs selected through the NIH Best 
Pharmaceuticals for Children Act (BPCA) prioritization initiative. The lessons learned 
through the studies evaluated in this dissertation were incorporated into the design of the 
POPS study, which will begin enrollment by the end of 2011. Another initiative to validate 
the use of alternative biological sample collection techniques is in process. The DBS 
technology will be expanded to other body fluids (i.e., dried matrix spots, dried urine spots) 
to evaluate the PK of anti-staphylococcal antibiotics in children. The study design and 
funding sources are being assembled for this project. 
 In summary, minimal-risk methods can revolutionize the way drug development is 
conducted in preterm infants and can be extrapolated to older pediatric populations. Clearly 
defined objectives for minimal-risk methods are important to achieve the appropriate balance 
between study feasibility and data quality. In the future, validation of minimal-risk methods 
will provide additional evidence of the utility of these approaches. Minimal-risk methods can 
be applied to other commonly used therapeutics in children to decrease the profound 
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